UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549




FORM 10-Q


(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

2023


or


TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to

_________

Commission File No.Number: 001-39486


QUANTUM-SI INCORPORATED
(Exact name of registrant as specified in its charter)



HIGHCAPE CAPITAL ACQUISITION CORP.
(Exact name of registrant as specified in its charter)

Delaware
 85-1388175
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification No.)


452 Fifth Avenue, 21st Floor

New York, New York 10018

29 Business Park Drive
Branford, Connecticut06405
(Address of Principal Executive Offices, including zip code)principal executive offices)(Zip Code)

(646) 793-3510
(Registrant’s telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)


(866) 688-7374
(Registrant’s telephone number, including area code)

Not applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class 
Trading
Symbol(s)
 Name of each exchange on which
registered
Units, each consisting of one share of Class A common stock, and one-third of one redeemable warrant$0.0001 per share
 CAPAUQSI
 The Nasdaq Stock Market LLC
Class A common stock, par value $0.0001 per shareCAPAThe Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share
 CAPAW
QSIAW
 
The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ¨ No x


Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


¨
Large accelerated filer
¨
Accelerated filer
x
Non-accelerated filer
x
Smaller reporting company

 x
Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):. Yes x No ¨


As of November 12, 2020, there were 11,905,0002, 2023, the registrant had 121,790,534 shares of Class A common stock outstanding and 2,875,00019,937,500 shares of Class B common stock ofoutstanding.



QUANTUM-SI INCORPORATED
FORM 10-Q
For the registrant issued and outstanding.

quarterly period ended September 30, 2023


HIGHCAPE CAPITAL ACQUISITION CORP.

Quarterly Report on Form 10-Q

TABLE OF CONTENTS


  Page
PART 1 – FINANCIAL INFORMATION3
   
Part I4
 
Item 1.14
   
 14
   
 25
   
 36
   
 47
   
 58
   
Item 2.1422
   
Item 3.1632
   
Item 4.1632
   
PARTPart II – OTHER INFORMATION33
   
Item 1.1733
   
Item 1A.1733
   
Item 2.1734
   
Item 3.1734
   
Item 4.1734
   
Item 5.1734
   
Item 6.1735
   
1936

i


PART I – FINANCIAL INFORMATION

ITEM 1.  CONDENSED FINANCIAL STATEMENTS

HIGHCAPE CAPITAL ACQUISITION CORP.

CONDENSED BALANCE SHEET

SEPTEMBER 30, 2020

(Unaudited)

ASSETS    
Current assets    
Cash $1,164,723 
Prepaid expenses  174,605 
Total Current Assets  1,339,328 
     
Cash and cash equivalents held in Trust Account  115,000,384 
TOTAL ASSETS $116,339,712 
     
LIABILITIES AND STOCKHOLDERS’ EQUITY    
Current liabilities    
Accounts payable and accrued expenses $43,342 
Accrued offering costs  45,000 
Total Current Liabilities  88,342 
     
Deferred underwriting fee payable  4,025,000 
Total Liabilities  4,113,342 
     
Commitments and Contingencies    
     
Class A common stock subject to possible redemption, 10,722,636 shares at $10.00 per share  107,226,360 
     
Stockholders’ Equity    
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding   
Class A common stock, $0.0001 par value; 380,000,000 shares authorized; 1,182,364 issued and outstanding (excluding 10,722,636 shares subject to possible redemption)  118 
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 2,875,000 shares issued and outstanding  288 
Additional paid-in capital  5,050,857 
Accumulated deficit  (51,253)
Total Stockholders’ Equity  5,000,010 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $116,339,712 

The accompanying notes are an integral part ofIn this Quarterly Report on Form 10-Q, the unaudited condensed financial statements.


HIGHCAPE CAPITAL ACQUISITION CORP.

CONDENSED STATEMENT OF OPERATIONS

(Unaudited)

  Three Months
Ended
September 30,
  For the Period
from June 10,
2020 (Inception)
Through
September 30,
 
  2020  2020 
Formation and general and administrative expenses $50,637  $51,637 
Loss from operations  (50,637)  (51,637)
         
Other income:        
Interest earned on cash and cash equivalents held in Trust Account  384   384 
         
Net loss $(50,253) $(51,253)
         
Weighted average shares outstanding of Class A redeemable common stock  11,500,000   11,500,000 
Basic and diluted income per share, Class A redeemable common stock $0.00  $0.00 
         
Weighted average shares outstanding of Class A and Class B non-redeemable common stock  3,280,000   3,280,000 
Basic and diluted net loss per share, Class A and Class B non-redeemable common stock $(0.02) $(0.02)

The accompanying notes are an integral part ofterms “we”, “us”, “our”, the unaudited condensed financial statements.

2

HIGHCAPE CAPITAL ACQUISITION CORP.

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE PERIOD FROM JUNE 10, 2020 (INCEPTION) THROUGH SEPTEMBER 30, 2020

(Unaudited)

  Class A  Class B  Additional     Total 
  Common Stock  Common Stock  Paid-in  Accumulated  Stockholders’ 
  Shares  Amount  Shares  Amount  Capital  Deficit  Equity 
Balance – June 10, 2020 (inception)    $     $  $  $  $ 
                             
Issuance of Class B common stock to Sponsors        2,875,000   288   24,712      25,000 
                             
Net loss                 (1,000)  (1,000)
                             
Balance – June 30, 2020        2,875,000   288   24,712   (1,000)  24,000 
                             
Sale of 11,500,000 Units, net of underwriting discounts  11,500,000   1,150         108,201,473      108,202,623 
                             
Sale of 405,000 Private Placement Units  405,000   41         4,049,959      4,050,000 
                             
Common stock subject to possible redemption  (10,722,636)  (1,073)        (107,225,287)     (107,226,360)
                             
Net loss                 (50,253)  (50,253)
                             
Balance – September 30, 2020  1,182,364  $118   2,875,000  $288  $5,050,857  $(51,253) $5,000,010 

The accompanying notes are an integral part of the unaudited condensed financial statements.

3

HIGHCAPE CAPITAL ACQUISITION CORP.

CONDENSED STATEMENT OF CASH FLOWS

FOR THE PERIOD FROM JUNE 10, 2020 (INCEPTION) THROUGH SEPTEMBER 30, 2020

(Unaudited)

Cash Flows from Operating Activities:    
Net loss $(51,253)
Adjustments to reconcile net loss to net cash used in operating activities:    
Interest earned on marketable securities held in Trust Account  (384)
Changes in operating assets and liabilities:    
Prepaid expenses  (174,605)
Accrued expenses  43,342 
Net cash used in operating activities  (182,900)
     
Cash Flows from Investing Activities:    
Investment of cash into Trust Account  (115,000,000)
Net cash used in investing activities  (115,000,000)
     
Cash Flows from Financing Activities:    
Proceeds from issuance of Class B common stock to Sponsor  25,000 
Proceeds from sale of Units, net of underwriting discounts paid  112,700,000 
Proceeds from sale of Private Placement Units  4,050,000 
Repayment of promissory note - related party  (99,627)
Payment of offering costs  (327,750)
Net cash provided by financing activities  116,347,623 
     
Net Change in Cash  1,164,723 
Cash – Beginning of period   
Cash – End of period $1,164,723 
     
Supplemental Disclosure of Non-Cash Investing and Financing Activities:    
Offering costs included in accrued offering costs $45,000 
Initial classification of Class A common stock subject to possible redemption $107,276,620 
Change in value of Class A common stock subject to possible redemption $(50,260)
Deferred underwriting fee payable $4,025,000 
Payment of deferred offering costs through promissory note – related party $99,627 

The accompanying notes are an integral part of the unaudited condensed financial statements.


HIGHCAPE CAPITAL ACQUISITION CORP.
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2020
(Unaudited) 

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

“Company” or “Quantum-Si” mean Quantum-Si Incorporated (formerly HighCape Capital Acquisition Corp. (the “Company”) and our subsidiaries. Quantum-Si Incorporated was incorporated in Delaware on June 10, 2020. The Company was formed for the purpose of effectingCompany’s legal name became Quantum-Si Incorporated following a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businessesbetween the Company and Q-SI Operations Inc. (formerly Quantum-Si Incorporated) on June 10, 2021 (the “Business Combination”). The Company is not limited to a particular industry or sector for purposes


2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on September 3, 2020. On September 9, 2020 the Company consummated the Initial Public Offering of 11,500,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), whichForm 10-Q includes the full exercise by the underwriters of their over-allotment option in the amount of 1,500,000 Units, at $10.00 per Unit, generating gross proceeds of $115,000,000 which is described in Note 3.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 405,000 units (the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to HighCape Capital Acquisition, LLC, a Delaware limited liability company (the “Sponsor”), generating gross proceeds of $4,050,000, which is described in Note 4.

Transaction costs amounted to $6,797,377, consisting of $2,300,000 of underwriting fees, $4,025,000 of deferred underwriting fee and $472,377 of other offering costs. In addition, at September 9, 2020, cash of $1,419,450 was held outside of the Trust Account (as defined below) and is available for working capital purposes.

Following the closing of the Initial Public Offering on September 9, 2020, an amount of $115,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account (the “Trust Account”) located in the United States and will be invested only in U.S. government securities,forward-looking statements within the meaning set forth inof Section 2(a)(16)27A of the Investment CompanySecurities Act of 1940,1933, as amended (the “Investment Company“Securities Act”), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds held in the Trust Account, as described below.

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act.

The Company will provide the holders of the outstanding Public Shares (the “Public Stockholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.00 per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants.


HIGHCAPE CAPITAL ACQUISITION CORP.
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2020
(Unaudited)

The Company will only proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 following any related redemptions and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination. If a stockholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (“SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain stockholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder approval in connection with a Business Combination, the Company’s Sponsor and any other holders of the Company’s common stock prior to the Initial Public Offering (the “initial stockholders”) have agreed to vote their Founder Shares (as defined in Note 5), Private Placement Shares (as defined in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.

If the Company seeks stockholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Certificate of Incorporation will provide that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 1321E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), that relate to future events, our future operations or financial performance, or our plans, strategies and prospects. These statements are based on the beliefs and assumptions of our management team. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure that we will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares, without the prior consent of the Company.

The Sponsor has agreed (a) to waive its redemption rights with respect to the Founder Shares, Private Placement Shares and Public Shares held by it in connection with the completion of a Business Combination and (b) not to propose an amendment to the Certificate of Incorporation (i) to modify the substanceachieve or timing of the Company���s obligation to allow redemptions in connection with a Business Combinationrealize these plans, intentions or to redeem 100% of its Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other provision relating to stockholders’ rights or pre-business combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.

The Company will have until September 9, 2022 to complete a Business Combination (the “Combination Period”). If the Company has not completed a Business Combination by the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (net of permitted withdrawals and less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption,expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or performance, are forward-looking statements. These statements may be preceded by, followed by or include the approvalwords “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates” or “intends” or the negative of these terms, or other comparable terminology intended to identify statements about the Company’s remaining stockholdersfuture, although not all forward-looking statements contain these identifying words. The forward-looking statements are based on projections prepared by, and are the Company’s boardresponsibility of, directors, dissolve and liquidate, subjectour management. Forward-looking statements contained in each casethis Quarterly Report on Form 10-Q include, but are not limited to, the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period.

The Sponsor has agreed to waive its liquidation rights with respect to the Founder Shares and Private Placement Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor acquires Public Shares in or after the Initial Public Offering, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will bestatements about:



the potential attributes and benefits of our commercialized PlatinumTM protein sequencing instrument and our other products once commercialized;

the success, cost and timing of our product development activities;

the commercialization and adoption of our existing products and the success of any product we may offer in the future;

our manufacturing capabilities;

our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any approved product;

the ability to maintain the listing of our Class A common stock on The Nasdaq Stock Market LLC (“Nasdaq”);

our ongoing leadership transitions and our success in retaining or recruiting, or changes in, our officers, key employees or directors;

our ability to identify, in-license or acquire additional technology;

our intellectual property rights;

our ability to maintain our existing license agreements and manufacturing arrangements;

our ability to compete with other companies currently marketing or engaged in the development of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than us;

the size and growth potential of the markets for our products, and the ability of each product to serve those markets once commercialized, either alone or in partnership with others;

our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

our financial performance;

changes in applicable laws or regulations;

market conditions and global and economic factors, such as inflation; and

our ability to raise financing in the future.

These forward-looking statements are based on information available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of this report, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Important factors could cause actual results, performance or achievements to differ materially from those indicated or implied by forward-looking statements such as those described under the liquidationcaption “Risk Factors” in Item 1A of Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, in Item 1A of Part II of our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023, and in other filings that we make with the Securities and Exchange Commission. The risks described under the heading “Risk Factors” are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the Trust Account, if less than $10.00date hereof. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


3

PART I – FINANCIAL INFORMATION

Item 1.Financial Statements

QUANTUM-SI INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per public Share due to reductions share amounts)
(Unaudited)

  
September 30,
2023
  
December 31,
2022
 
Assets      
Current assets:      
Cash and cash equivalents 
$
93,822
  
$
84,319
 
Marketable securities  180,803   266,990 
Accounts receivable, net of allowance for estimated credit losses of $0 and $0, respectively  466   - 
Inventory, net
  2,325   - 
Prepaid expenses and other current assets  
7,392
   
6,873
 
Total current assets  284,808   358,182 
Property and equipment, net  
17,606
   
16,849
 
Internally developed software
  627   - 
Operating lease right-of-use assets  
14,354
   
15,757
 
Other assets  701   697 
Total assets $318,096  $391,485 
Liabilities and stockholders’ equity
        
Current liabilities:        
Accounts payable 
$
2,056
  
$
3,903
 
Accrued expenses and other current liabilities  
7,428
   
10,434
 
Current portion of operating lease liabilities
  1,523   1,369 
Total current liabilities  11,007   15,706 
Warrant liabilities  
1,077
   
996
 
Other long-term liabilities  
19
   
-
 
Operating lease liabilities
  13,928   16,077 
Total liabilities  26,031   32,779 
         
Commitments and contingencies (Note 15)      
         
Stockholders’ equity
        
Class A Common stock, $0.0001 par value; 600,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 121,790,534 and 120,006,757 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
  
12
   
12
 
Class B Common stock, $0.0001 par value; 27,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 19,937,500 shares issued and outstanding as of September 30, 2023 and December 31, 2022
  
2
   
2
 
Additional paid-in capital  
765,637
   
758,366
 
Accumulated deficit  
(473,586
)
  
(399,674
)
Total stockholders’ equity
  292,065   358,706 
Total liabilities and stockholders’ equity
 $318,096  $391,485 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

QUANTUM-SI INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
 (in thousands, except share and per share amounts)
(Unaudited)

  Three months ended September 30,  Nine months ended September 30, 
  2023
  2022
  2023
  2022
 
Revenue:
            
Product $216  $-  $654  $- 
Service  7   -   28   - 
Total revenue
  223   -   682   - 
Cost of revenue
  115   -   372   - 
Gross profit  108   -   310   - 
Operating expenses:                
Research and development  
16,587
   
16,675
   
50,588
   
53,905
 
Selling, general and administrative  
10,696
   
10,983
   
33,010
   
31,093
 
Total operating expenses  27,283   27,658   83,598   84,998 
Loss from operations  (27,175)  (27,658)  (83,288)  (84,998)
Dividend income  2,572   1,381   7,274   3,288 
Unrealized gain (loss) on marketable securities
  1,953   (4,240)  8,302   (20,384)
Realized loss on marketable securities
  (1,901)  (1,348)  (6,489)  (2,399)
Change in fair value of warrant liabilities  
(162
)
  
137
   
(81
)
  
5,121
 
Other income (expense), net  
(15
)
  
15
   
370
   
70
 
Loss before provision for income taxes  (24,728)  (31,713)  (73,912)  (99,302)
Provision for income taxes  
-
   
-
   
-
   
-
 
Net loss and comprehensive loss $(24,728) $(31,713) $(73,912) $(99,302)
Net loss per common share attributable to common stockholders, basic and diluted 
$
(0.17
)
 
$
(0.23
)
 
$
(0.52
)
 
$
(0.71
)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted  
141,660,018
   
139,542,660
   
141,154,110
   
139,057,663
 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

QUANTUM-SI INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(in the valuethousands, except share amounts)
(Unaudited)

  
Class A
common stock
  
Class B
common stock
  Additional
paid-in
capital
  Accumulated
deficit
  
Total
stockholders’
equity
 
  Shares  Amount  Shares  Amount       
Balance - December 31, 2022
  120,006,757  $12   19,937,500  $2  $758,366  $(399,674) $358,706 
Net loss  -   -   -   -   -   (23,611)  (23,611)
Common stock issued upon vesting of restricted stock units  1,552,583   -   -   -   -   -   - 
Stock-based compensation  -   -   -   -   3,908
  -   3,908
Balance - March 31, 2023
  121,559,340  $12   19,937,500  $2  $762,274  $(423,285) $339,003 
Net loss  -   -   -   -   -   (25,573)  (25,573)
Common stock issued upon vesting of restricted stock units  74,273   -   -   -   -   -   - 
Stock-based compensation  -   -   -   -   1,865   -   1,865 
Balance - June 30, 2023
  121,633,613  $12   19,937,500  $2  $764,139  $(448,858) $315,295 
Net loss  -   -   -   -   -   (24,728)  (24,728)
Common stock issued upon exercise of stock options and vesting of restricted stock units  156,921   -   -   -   357   -   357 
Stock-based compensation  -   -   -   -   1,141   -   1,141 
Balance - September 30, 2023
  121,790,534  $12   19,937,500  $2  $765,637  $(473,586) $292,065 


  
Class A
common stock
  
Class B
common stock
  
Additional
paid-in
capital
  Accumulated
deficit
  
Total
stockholders’
equity
 
  Shares  Amount  Shares  Amount       
Balance - December 31, 2021  118,025,410  $12   19,937,500  $2  $744,252  $(267,232) $477,034 
Net loss  -   -   -   -   -   (35,175)  (35,175)
Common stock issued upon exercise of stock options and vesting of restricted stock units  946,987   -   -   -   730   -   730 
Stock-based compensation  -   -   -   -   (714)  -   (714)
Balance - March 31, 2022  118,972,397  $12   19,937,500  $2  $744,268  $(302,407) $441,875 
Net loss  -   -   -   -   -   (32,414)  (32,414)
Common stock issued upon exercise of stock options and vesting of restricted stock units  271,731   -   -   -   264   -   264 
Stock-based compensation  -   -   -   -   3,770   -   3,770 
Balance - June 30, 2022  119,244,128  $12   19,937,500  $2  $748,302  $(334,821) $413,495 
Net loss  -   -   -   -   -   (31,713)  (31,713)
Common stock issued upon exercise of stock options and vesting of restricted stock units  604,042   -   -   -   1,625   -   1,625 
Stock-based compensation  -   -   -   -   4,043   -   4,043 
Balance - September 30, 2022  119,848,170  $12   19,937,500  $2  $753,970  $(366,534) $387,450 

The accompanying notes are an integral part of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiverthese unaudited condensed consolidated financial statements.

QUANTUM-SI INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in the Trust Account nor will it apply to any claims under the Company’s indemnitythousands)
(Unaudited)

  Nine Months Ended September 30,
 
  2023
  2022
 
Cash flows from operating activities:      
Net loss 
$
(73,912
)
 
$
(99,302
)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization
  3,063   1,789 
Non-cash lease expense
  1,486
   1,273 
Unrealized (gain) loss on marketable securities
  (8,302)  20,384 
Realized loss on marketable securities
  6,489   2,399 
(Gain) loss on disposal of fixed assets
  (8)  9 
Change in fair value of warrant liabilities  81   (5,121)
Change in fair value of contingent consideration  (400)  141
 
Stock-based compensation  6,914   7,099 
Changes in operating assets and liabilities:        
Accounts receivable, net  (466)  - 
Inventory, net
  (2,325)  - 
Prepaid expenses and other current assets  (236)  (931)
Operating lease right-of-use assets  (83)  (9,466)
Other assets
  (4)  (7)
Accounts payable  (732)  (444)
Accrued expenses and other current liabilities  (2,656)  2,224 
Other long-term liabilities
  19   - 
Operating lease liabilities  (1,995)  8,976 
Net cash used in operating activities $(73,067) $(70,977)
Cash flows from investing activities:        
Purchases of property and equipment  (4,877)  (7,241)
Internally developed software - capitalized costs
  (763)  - 
Purchases of marketable securities  -   (834)
 Sales of marketable securities  88,000   119,759 
Net cash provided by investing activities
 $82,360  $111,684 
Cash flows from financing activities:        
Proceeds from exercise of stock options  357   2,619 
Deferred offering costs
  (147)  - 
Payment of contingent consideration - business acquisition  -   (348)
Payment of deferred consideration - business acquisition  -   (500)
Net cash provided by financing activities $210  $1,771 
Net increase in cash and cash equivalents
  9,503   42,478 
Cash and cash equivalents at beginning of period  84,319   35,785 
Cash and cash equivalents at end of period
 $93,822  $78,263 
Supplemental disclosure of non-cash investing and financing activities:
        
Property and equipment purchased but not paid
 
$
59
  
$
798
 
Deferred offering costs payable
  136   - 

The accompanying notes are an integral part of the underwritersthese unaudited condensed consolidated financial statements.

QUANTUM-SI INCORPORATED

HIGHCAPE CAPITAL ACQUISITION CORP.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2020
(in thousands, except share and per share amounts)
(Unaudited)

NOTE


1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Quantum-Si Incorporated (including its subsidiaries, the “Company” or “Quantum-Si”) (formerly HighCape Capital Acquisition Corp. (“HighCape”)) was incorporated in Delaware on June 10, 2020. The Company’s legal name became Quantum-Si Incorporated following a business combination between the Company and Q-SI Operations Inc. (formerly Quantum-Si Incorporated) on June 10, 2021 (the “Business Combination”).


The Company is an innovative life sciences company with the mission of transforming single-molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome, the set of proteins expressed within a cell. The Company has developed a proprietary universal single-molecule detection platform that the Company is first applying to proteomics to enable Next-Generation Protein SequencingTM (“NGPS”), the ability to sequence proteins in a massively parallel fashion (rather than sequentially, one at a time), and can be used for the study of nucleic acids. The Company’s platform is currently comprised of the Platinum™ NGPS instrument and the Quantum-Si Cloud software service, and reagent kits and chips for use with its instruments.

Although the Company has incurred recurring losses each year since its inception, the Company expects its cash and cash equivalents, and marketable securities will be able to fund its operations for at least the next twelve months.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) forand pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. All intercompany transactions are eliminated. Certain information and in accordance with the instructions to Form 10-Q and Regulation S-X of the SEC. Certain information or footnotenote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to thesuch rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unauditedregulations.

These condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensedconsolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s final prospectus for its Initial Public Offering as filed with the SEC on September 4, 2020, as well as the audited balance sheet included in the Company’s CurrentAnnual Report on Form 8-K,10-K for the year ended December 31, 2022. The condensed consolidated balance sheet as filed withof December 31, 2022 included herein was derived from the SECaudited consolidated financial statements as of that date, but does not include all disclosures, including certain notes required by U.S. GAAP, on September 9, 2020an annual reporting basis.


In the opinion of management, the accompanying condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and September 15, 2020.cash flows for the interim periods. The interim results for the three and nine months ended September 30, 2020 and for the period from June 10, 2020 (inception) through September 30, 20202023 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 20202023, or any other period.

Except for any future interim periods.

Emerging Growth Company

The Company isrevenue, inventory and capitalized software development costs discussed elsewhere in this note, there have been no material changes to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Global Developments
In 2022, various central banks around the world (including the Federal Reserve in the United States) raised interest rates. These rate increases have caused an “emerging growth company,” as definedoverall decline in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparisonfair value of the Company’s fixed income mutual funds to date. The impact of such rate changes on the overall financial markets and the economy may continue to impact the Company in the future, including by making capital more difficult and costly to obtain on reasonable terms and when needed. In addition, the global economy has experienced and is continuing to experience high levels of inflation and global supply chain disruptions. The Company continues to monitor these supply chain, inflation and interest rate factors, as well as the uncertainty resulting from the overall economic environment.


In addition, although the Company has no operations in or direct exposure to Russia or Ukraine, the Company has experienced some constraints in product and material availability and increasing costs required to obtain some materials and supplies as a result of the impact of the Russia-Ukraine military conflict on the global economy, which has contributed to the global supply chain disruptions. To date, the Company’s business has not been materially impacted by the conflict. However, as the conflict continues or worsens, it may adversely impact the Company’s business, financial condition, results of operations or cash flows.

Concentration of Business Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and marketable securities. As of September 30, 2023 and December 31, 2022, substantially all of the Company’s marketable securities were invested in fixed income mutual funds at one financial institution. See Note 5 “Investments in Marketable Securities” in our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for further information regarding our realized losses on such accounts. The Company also maintains balances in certain operating accounts above federally insured limits and, as a result, the Company is exposed to credit risk in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation.

The Company sources certain key materials and components utilized in the Company’s products from single or limited suppliers. Historically, the Company has not experienced significant issues sourcing these materials and components. However, if these suppliers were not able to supply the requested amount of materials or components, it could take a considerable length of time to obtain alternative sources, which could affect the Company’s development efforts and commercial operations.

Segment Reporting



The Company’s Chief Operating Decision Maker, its Chief Executive Officer, reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates as a single reportable segment.

Reclassifications
Certain prior year amounts have been reclassified for consistency with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

current year’s presentation.


Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires managementthe Company to make estimates and assumptions about future events that affect the amounts reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of thein its condensed consolidated financial statements and the reported amounts of revenuesaccompanying notes. Future events and expenses during the reporting period.

Makingtheir effects cannot be determined with certainty. On an ongoing basis, management evaluates these estimates requires management to exercise significant judgment. It is at least reasonably possibleand assumptions. Significant estimates and assumptions include:



valuation allowance with respect to deferred tax assets;


inventory valuation;


assumptions used for leases;


valuation of warrant liabilities;


assumptions associated with revenue recognition; and


assumptions underlying the fair value used in the calculation of stock-based compensation.

The Company bases these estimates on historical and anticipated results and trends and on various other assumptions that the estimate ofCompany believes are reasonable under the effect of a condition, situation or set of circumstances, that existed at the date of the financial statements, which management consideredincluding assumptions as to future events. Changes in formulating its estimate, could changeestimates are recorded in the near term due to one or more future events. Accordingly, the actualperiod in which they become known. Actual results could differ significantly from those estimates.

Cashestimates, and Cash Equivalents

The Company considers all short-term investmentsany such differences may be material to the Company’s condensed consolidated financial statements.


Inventory, Net

Inventory is stated at the lower of cost or net realizable value with an original maturitycost determined using the first-in, first-out method. Inventory primarily consists of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalentsraw materials and finished goods of $1,030 and $1,285, respectively, as of September 30, 2020.

Class A Common Stock Subject2023.



Materials that may be utilized for either research and development or, alternatively, for commercial purposes, are classified as inventory. Amounts in inventory that are used for research and development purposes are charged to Possible Redemption

research and development expense when the product enters the research and development process and can no longer be used for commercial purposes and, therefore, does not have an “alternative future use” as defined in authoritative guidance.




The Company accountsperforms an assessment of the recoverability of capitalized inventory during each reporting period and, if needed, writes down any excess and obsolete inventory to its estimated net realizable value in the period it is identified. As of September 30, 2023, there were no write-downs recorded against inventory.

Capitalized Software Development Costs

The Company capitalizes certain internal use software development costs related to its SaaS platform incurred during the application development stage when management with the relevant authority authorizes and commits to the funding of the project, it is probable that the project will be completed, and the software will be used as intended. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable that the expenditure will result in additional functionality. Costs related to preliminary project activities and to post-implementation activities are expensed as incurred. Internal use software is amortized on a straight-line basis over its estimated useful life, which is generally two years. Management evaluates the useful lives of these assets on an annual basis and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized costs are recorded as Internally developed software in the condensed consolidated balance sheets. There was no Internally developed software recorded in 2022. Amortization expense related to internally developed software was $90 and $136 for the three and nine months ended September 30, 2023, respectively.  As of September 30, 2023 amortization expense is expected to be $95 for the remainder of the year ending December 31, 2023 and $382 and $150 for the years ending December 31, 2024 and 2025, respectively.

Revenue Recognition

The Company’s revenue is derived from sales of products and services. Product revenue is primarily generated from the sales of instruments and consumables used in protein sequencing and analysis. Service revenue is primarily generated from service maintenance contracts including cloud access, proof of concept services and advanced training for instrument use. The Company recognizes revenue when or as a customer obtains control of the promised goods and services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue as the performance obligations have been satisfied. Revenue recognition for contracts with multiple deliverables is based on the separate satisfaction of each distinct performance obligation within the contract. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company allocates transaction price to the performance obligations in a contract with a customer based on the relative standalone selling price of each performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information and specific factors such as competitive positioning, internal costs, profit objectives, and internally approved pricing guidelines related to the performance obligation. 

The Company considers performance obligation for sales of products is satisfied upon shipment of the goods to the customer in accordance with the shipping terms (either upon shipment or delivery), which is when control of the product is deemed to be transferred; this would include instruments and consumables. Customers generally do not have a right of return, except for defective or damaged products during the warranty period or unless prior written consent is provided. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Revenues for service maintenance contracts, which start after the first year of purchase and are considered as service type warranties that effectively extend the standard first-year warranty coverage at the customer’s option, are recognized ratably over the contract service period as these services are performed evenly over time. Revenues for proof of concept services and advanced training is recognized upon satisfaction of the underlying performance obligation. The Company typically provides a standard one-year warranty which covers defects in materials and workmanship and manufacturing or performance conditions under normal use and service for the first year. The first year of the warranty of the products is considered an assurance-type warranty. The Company has determined that this standard first-year warranty is not a distinct performance obligation.

The Company disaggregates revenue from contracts with customers by type of revenue – products and services. The Company believes that product revenue and service revenue aggregate the payor types by nature, amount, timing and uncertainty of its revenue streams. Total revenue generated from domestic sales for the three and nine months ended September 30, 2023 was $209 and $565, respectively. Total revenue generated from international sales for the three and nine months ended September 30, 2023 was $14 and $117.

Deferred Revenue

Deferred revenue is a contract liability that consists of customer payments received in advance of performance or billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period.


Deferred revenue primarily consists of billings and payments received in advance of revenue recognition from service maintenance contracts including software subscription, proof of concept services and advanced training, and is reduced as the revenue recognition criteria are met. Deferred revenue also includes proof of concept services and advanced training provided to customers until the service has been performed. Deferred revenue is classified as current or non-current based on expected revenue recognition timing. Specifically, deferred revenue that will be recognized as revenue within the succeeding 12-month period is recorded as current and is included within Accrued expenses and other current liabilities, and the portion of deferred revenue where revenue is expected to be recognized beyond 12 months from the reporting date is recorded as non-current deferred revenue and is included in Other long-term liabilities in the Company’s condensed consolidated balance sheets.



As of September 30, 2023, the Company had deferred revenue amounting to $189, $170 of which is included within Accrued expenses and other current liabilities and $19 is included within Other long-term liabilities in the Company’s condensed consolidated balance sheets. The Company expects to recognize approximately 74% of its remaining performance obligations as revenue for the remainder of the year ending December 31, 2023, and an additional 26% for the year ending December 31, 2024 and thereafter.



The amount of revenue recognized during the three and nine months ended September 30, 2023 that was included in the deferred revenue balance of $73 at December 31, 2022 was $1 and $71, respectively.


Warranty

The Company provides a free 12-month assurance-type warranty to customers with the initial purchase of a PlatinumTM instrument. The cost of the warranty is accrued upon the initial sale of an instrument in Accrued expenses and other current liabilities on the condensed consolidated balance sheets.


Shipping and Handling Costs



Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as fulfillment costs and are included in Cost of revenue in the condensed consolidated statements of operations and comprehensive loss. Shipping and handling costs billed to customers are considered part of the transaction price and are recognized as revenue with the underlying product sales.

Recently Issued Accounting Pronouncements
Accounting pronouncements issued but not yet adopted

No new accounting pronouncements issued or effective during the three and nine months ended September 30, 2023 had, or are expected to have, a material impact on the Company’s condensed consolidated financial statements.

3. ACQUISITION

Majelac Technologies LLC

Pursuant to the terms and conditions of an Asset Purchase Agreement by and among the Company, Majelac Technologies LLC (“Majelac”), and certain other parties, on November 5, 2021 (the “Majelac Closing Date”), the Company acquired certain assets and assumed certain liabilities of Majelac, a privately-owned company providing semiconductor chip assembly and packaging capabilities located in Pennsylvania, for $4,632 in cash including $132 in reimbursement for certain recently purchased equipment, and 535,715 shares of Class A common stock, valued at $4,232, issued to Majelac subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”certain restrictions. An additional 59,523 shares of Class A common stock subjectvalued at $471 were issued to mandatory redemption is classified as a liability instrumentMajelac 12 months after the Majelac Closing Date on November 7, 2022. The Company also assumed the legal fees of Majelac of $50. Additional purchase price consideration of $500 in cash was to be paid six months after the Majelac Closing Date less any amount that could be required by the buyer indemnitees to satisfy any unresolved claims for indemnification, if any. The Company agreed to pay additional milestone-based consideration of up to $800, which was fair valued at $531 on the Majelac Closing Date. On May 4, 2022, the Company paid Majelac $900 in cash, which consisted of $500 for the additional purchase price consideration and is measured$400 (fair value of $348 at the Majelac Closing Date) for the firstof two milestones that was met. As of June 30, 2023, the Company determined that the estimated fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the controlvalue of the holder or subject to redemption uponcontingent consideration was de minimis as the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outsideprobability of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at September 30, 2020, Class A common stock subject to possible redemption are presented as temporary equity, outside of the stockholders’ equity section of the Company’s condensed balance sheet.


HIGHCAPE CAPITAL ACQUISITION CORP.
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2020
(Unaudited)

Offering Costs

Offering costs consist of underwriting, legal, accounting and other expenses incurred through the Initial Public Offering that are directly related to the Initial Public Offering. Offering costs amounting to $6,797,377 were charged to stockholders’ equity upon the completion of the Initial Public Offering.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.second milestone being met by November 1, 2023 was remote. As of September 30, 2020,2023, there has been no change from the June 30, 2023 determination. As a result, the Company hadrecorded a deferred tax assetgain of approximately $11,000, due to start-up and organizational expenses, which had a full valuation allowance recorded against it of approximately $11,000.

The Company’s currently taxable income primarily consists of interest income on$400 during the Trust Account. The Company’s general and administrative costs are generally considered start-up costs and are not currently deductible. During the threenine months ended September 30, 2023 in Other income (expense), net in the condensed consolidated statements of operations and comprehensive loss.


The acquisition brought semiconductor chip assembly and packaging capabilities in-house and secured the Company’s supply chain to support its commercialization efforts. Prior to the acquisition, Majelac was a vendor of the Company.

The following table summarizes the final purchase price allocation at the Majelac Closing Date as follows:

  
Purchase Price
Allocation
 
Prepaid expenses and other current assets 
$
27
 
Property and equipment, net  
906
 
Goodwill  
9,483
 
Total $10,416 

Goodwill represents the excess of the consideration transferred over the aggregate fair values of assets acquired and liabilities assumed. The goodwill recorded in connection with this acquisition was based on operating synergies and other benefits expected to result from the combined operations. The goodwill acquired is amortizable for tax purposes over a period of 15 years. During the fourth quarter ended December 31, 2022, the Company concluded the goodwill from the Majelac acquisition was fully impaired and recorded a charge of $9,483 on the consolidated statements of operations and comprehensive loss.

Acquisition-related costs recognized during the three and nine months ended September 30, 2022, including transaction costs such as legal, accounting, valuation and other professional services, were $0 and $26, respectively, and are included in Selling, general and administrative on the condensed consolidated statements of operations and comprehensive loss. There were no acquisition-related costs recognized during the three and nine months ended September 30, 2023.

4. FAIR VALUE OF FINANCIAL INSTRUMENTS
Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair value.
The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:


Level 1 -  Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has the ability to access.


Level 2 -  Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.


Level 3 -  Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The carrying value of cash and cash equivalents, accounts payable and accrued expenses and other current liabilities approximates their fair values due to the short-term or on demand nature of these instruments. Fixed income mutual funds were valued using quoted market prices and accordingly were classified as Level 1. There were no transfers between fair value measurement levels during the three and nine months ended September 30, 2023.

The Company’s outstanding warrants include publicly traded warrants (the “Public Warrants”) which were issued as one-third of one redeemable warrant per unit issued during HighCape’s initial public offering on September 9, 2020, and warrants sold in a private placement (the “Private Warrants”) to HighCape’s sponsor, HighCape Capital Acquisition LLC. The Company accounted for period from June 10, 2020 (inception) throughthe warrants as liabilities in accordance with ASC 815-40 and are presented as Warrant liabilities on the condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented as Change in fair value of warrant liabilities in the condensed consolidated statements of operations and comprehensive loss. There were no exercises or redemptions of the public or private warrants as of September 30, 2020,2023.

The Public Warrants and Private Warrants were carried at fair value as of September 30, 2023 and December 31, 2022. The Public Warrants were valued using Level 1 inputs as they are traded in an active market. The Private Warrants were valued using a binomial lattice model, which results in a Level 3 fair value measurement. The primary unobservable input utilized in determining the Companyfair value of the Private Warrants was the expected volatility of the Company’s Class A common stock. The expected volatility was based on consideration of the implied volatility from the Company’s own Public Warrant pricing and on the historical volatility observed at guideline public companies. As of September 30, 2023, the significant assumptions used in preparing the binomial lattice model for valuing the Private Warrants liability include (i) volatility of 93.7%, (ii) risk-free interest rate of 4.80%, (iii) strike price of $11.50, (iv) fair value of common stock of $1.66, and (v) expected life of 2.7 years. As of December 31, 2022, the significant assumptions used in preparing the binomial lattice model for valuing the Private Warrants liability include (i) volatility of 75.1%, (ii) risk-free interest rate of 4.10%, (iii) strike price of $11.50, (iv) fair value of common stock of $1.83, and (v) expected life of 3.4 years.
The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy:
     Fair Value Measurement Level 
September 30, 2023: Total  Level 1  Level 2  Level 3 
Assets:            
Cash and cash equivalents - Money Market
 
$
88,354
  
$
88,354
  
$
-
  
$
-
 
Marketable securities  180,803
   180,803
   -
   -
 
Total assets at fair value on a recurring basis $269,157  $269,157  $-  $- 
                 
Liabilities:                
Public Warrants 
$
1,035
  
$
1,035
  
$
-
  
$
-
 
Private Warrants  
42
   
-
   
-
   
42
 
Total liabilities at fair value on a recurring basis $1,077  $1,035  $-  $42 
     Fair Value Measurement Level 
December 31, 2022: Total  Level 1  Level 2  Level 3 
Assets:            
Cash and cash equivalents - Money Market
 
$
83,079
  
$
83,079
  
$
-
  
$
-
 
Marketable securities  266,990   266,990   -   - 
Total assets at fair value on a recurring basis
 $350,069  $350,069  $-  $- 
                 
Liabilities:                
Public Warrants 
$
958
  
$
958
  
$
-
  
$
-
 
Private Warrants  
38
   
-
   
-
   
38
 
Total liabilities at fair value on a recurring basis $996  $958  $-  $38 

5. INVESTMENTS IN MARKETABLE SECURITIES

Unrealized gains/(losses) related to securities held as of September 30, 2023, realized losses related to securities that were sold during the three and nine months ended September 30, 2023 and dividend income from marketable securities were as follows for the three and nine months ended September 30, 2023 and 2022:

  
Three months ended
September 30,
  
Nine months ended
September 30,
 
  2023  2022  2023  2022 
Unrealized gain (loss) on marketable securities $1,953  $(4,240) $8,302  $(20,384)
Realized loss on marketable securities  (1,901)  (1,348)  (6,489)  (2,399)
Dividend income from marketable securities  2,572   1,381   7,274   3,288 

6. PROPERTY AND EQUIPMENT, NET
Property and equipment, net, are recorded no income tax expense. The Company’s effective tax rateat historical cost and consist of the following:

  
  September 30,
2023
  
December 31,
2022
 
Laboratory and production equipment
 
$
14,880
  
$
14,031
 
Computer equipment
  
1,736
   
1,073
 
Purchased software
  
188
   
188
 
Furniture and fixtures
  
260
   
218
 
Leasehold improvements  6,918   1,308 
Construction in process
  
2,776
   
6,234
 
Property and equipment, gross  
26,758
   
23,052
 
Less: Accumulated depreciation and amortization
  
(9,152
)
  
(6,203
)
Property and equipment, net $17,606  $16,849 
Depreciation and amortization expense associated with Property and equipment amounted to $1,080 and $729 for the three months ended September 30, 20202023 and 2022, respectively, and $2,927 and $1,789 for the period from June 10, 2020 (inception) throughnine months ended September 30, 2020 was zero, which differs from the expected income tax rate due to the start-up costs (discussed above) which are not currently deductible.

ASC 740 prescribes a recognition threshold2023 and a measurement attribute2022, respectively. No impairments were recorded for the financial statement recognitionthree and measurementnine months ended September 30, 2023 or 2022.


7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consist of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. the following:

  
September 30,
2023
  
December 31,
2022
 
Employee compensation and benefits
 
$
3,191
  
$
5,548
 
Contracted services
  
2,325
   
3,616
 
Restructuring costs  551   - 
Business acquisition costs and contingencies  -   343 
Legal fees
  
997
   
839
 
Other
  
364
   
88
 
Total accrued expenses and other current liabilities $7,428  $10,434 

8. LEASES

The Company recognizes accrued interesthas commitments under lease arrangements primarily for office and penaltiesmanufacturing space. The Company’s leases have initial lease terms ranging from two to 10 years. These leases include options to extend or renew the leases for an additional period of one to 10 years.

Operating leases are accounted for on the condensed consolidated balance sheets with right-of-use (“ROU”) assets being recognized in “Operating lease right-of-use assets” and lease liabilities recognized in “Current portion of operating lease liabilities” and “Operating lease liabilities”.

Lease-related costs for the three and nine months ended September 30, 2023  and 2022 are as follows:

  
Three months ended
September 30,
  
Nine months ended
September 30,
 
  2023
  2022
  2023
  2022
 
Operating lease cost $864  $819  $2,613  $2,352 
Variable lease cost  545   321   1,226   922 
Total lease cost $1,409  $1,140  $3,839  $3,274 

Other information related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penaltiesoperating leases as of September 30, 2020. 2023 and December 31, 2022 is as follows:

  September 30,

December 31,
  2023


2022

Weighted-average remaining lease term (years) 
6.6


7.3
Weighted-average discount rate 
7.9% 
7.9%

The following table provides certain cash flow and supplemental cash flow information related to the Company’s lease liabilities for the nine months ended September 30, 2023  and 2022:

  Nine months ended September 30, 
  2023
  2022
 
Operating cash paid to settle operating lease liabilities $3,201  $1,362 
         
Right-of-use assets obtained in exchange for lease liabilities $83  $9,466 

Future minimum lease payments under non-cancellable leases as of September 30, 2023 are as follows:

  Operating Leases 
Remainder of 2023 $1,097 
2024  4,436 
2025  4,527 
2026  4,585 
2027  4,549 
Thereafter  13,027 
Total undiscounted lease payments $32,221 
Less: Imputed interest  7,666 
Less: Lease incentives (1)
  9,104 
Total lease liabilities $15,451 

(1)
Includes lease incentives that may be realized in 2023 for the costs of leasehold improvements.

In December 2021, the Company signed a 10-year lease for approximately 67,000 square feet of space located at 115 Munson Street in New Haven, Connecticut.  The lease commenced on January 8, 2022 with rent payments beginning on July 7, 2022.  Under the lease, the landlord contractually agreed to reimburse the Company for up to $9,104 in improvements to the space, to be used for such improvements as the Company deems “necessary or desirable”.  On September 13, 2022, the Company filed a lawsuit against the landlord, alleging that the landlord has: (i) refused to reimburse the Company for costs related to improvements already incurred and submitted; (ii) delayed the Company’s completion of improvements, in order to avoid reimbursing the costs of those improvements; and (iii) improperly rejected the Company’s proposed improvement plans.

The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. 

Net Income (Loss) Per Common Share

Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common shares outstandingaccounted for the period. The$9,104 of lease incentives as an offset to the lease liability recorded at the inception of the lease.  From the total lease incentives, the Company has not consideredincurred and recognized leasehold improvements of approximately $1,100 related to reimbursable construction costs included in construction in progress within Property and equipment, net on the effectcondensed consolidated balance sheets as of warrants, sold inSeptember 30, 2023 and December 31, 2022.  Although the Initial Public Offering and inCompany believes it is contractually entitled to the sale$9,104 of lease incentives, based on the current status of the Private Placement Units, to purchase 3,968,333 shareslitigation, the Company cannot determine the likely outcome or estimate the impact on such carrying values.


9. STOCKHOLDERS’ EQUITY
At-the-market Equity Offering Program

In August 2023, the Company filed a universal shelf registration statement on Form S-3 (the “Shelf Registration Statement”), which became effective on August 22, 2023, covering the offering of Class A common stock, preferred stock, debt securities, warrants, rights and units.

In August 2023, the Company also entered into an Equity Distribution Agreement (“EDA”) with an outside placement agent (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s Class A common stock having an aggregate offering price of up to $75 million in “at-the-market” offerings through the Agent (the “ATM Offering”). The Shelf Registration Statement included a prospectus supplement covering the offering, issuance and sale of up to $75 million of the Company’s Class A common stock, from time to time, through the ATM Offering. The shares to be sold under the EDA may be issued and sold pursuant to the Shelf Registration Statement. The EDA also provides that the Agent will be entitled to compensation for its services in an amount up to 3.0% of the gross proceeds from the sales of shares sold through the Agent under the EDA. The Company has no obligation to sell any shares under the EDA and may at any time suspend solicitation and offers under the EDA. To date, the Company has not issued or sold any shares of the Company’s Class A common stock under the ATM Offering.

Equity Incentive Plan

The Company’s 2013 Employee, Director and Consultant Equity Incentive Plan, as amended on March 12, 2021 (the “2013 Plan”), was originally adopted by its Board of Directors and stockholders in September 2013. In connection with the closing of the Business Combination, the Company adjusted the equity awards. The adjustments to the awards did not result in incremental expense as the equitable adjustments were made pursuant to a preexisting nondiscretionary antidilution provision in the calculation2013 Plan, and the fair-value, vesting conditions, and classification are the same immediately before and after the modification. In connection with the Business Combination, HighCape’s stockholders approved and adopted the Quantum-Si Incorporated 2021 Equity Incentive Plan (the “2021 Plan”) and the Company no longer makes issuances under the 2013 Plan. The 2021 Plan provides for grants of diluted income (loss) per share, since the exercisestock options, stock appreciation rights, restricted stock, restricted stock units, and other stock or cash-based awards. Directors, officers and other employees of the warrantsCompany and its subsidiaries, as well as others performing consulting or advisory services for the Company, are contingent uponeligible for grants under the occurrence2021 Plan. As of future eventsSeptember 30, 2023 and December 31, 2022, there were 13,071,147 and 9,133,702 shares, respectively, available for issuance under the inclusion2021 Plan.
On November 9, 2022, the Company granted inducement awards consisting of 2,780,000 performance-based stock options to purchase Class A common stock pursuant to Nasdaq Rule 5635(c)(4). These awards were not granted pursuant to the 2013 Plan or the 2021 Plan.

On May 8, 2023, the Company adopted the 2023 Inducement Equity Incentive Plan (the “2023 Inducement Plan”) to reserve 3,000,000 shares of its common stock to be used exclusively for grants of awards to individuals that were not previously employees or directors of the Company as a material inducement to such warrants would be anti-dilutive.

individuals’ entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The Company’s unaudited condensed statementsterms and conditions of operations include a presentationthe 2023 Inducement Plan are substantially similar to those of income (loss) per sharethe 2021 Plan. As of September 30, 2023, there were 60,250 shares remaining available for common sharesissuance under the 2023 Inducement Equity Incentive Plan.


Stock options
During the nine months ended September 30, 2023, the Company granted an aggregate of 10,138,730 stock option awards to participants, with vesting subject to redemption in a manner similarthe participant’s continued employment with the Company through the applicable vesting dates. Stock-based compensation related to the two-class method of income per share. Net income per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the interest income earned on the Trust Account of $384options for the three months ended September 30, 20202023 and 2022 was $1,133 and $1,868, respectively.  Stock-based compensation related to stock options for the period from June 10, 2020 (inception) throughnine months ended September 30, 2020, less applicable franchise taxes2023 and 2022 was $5,728 and $5,169, respectively.
A summary of the stock option activity is presented in the table below:

  
Number of
Options
  
Weighted Average
Exercise Price
  
Weighted Average
Remaining
Contractual Term
(Years)
  
Aggregate
Intrinsic Value
 
Outstanding at December 31, 2022  19,427,755  $3.69   8.68  $378 
Granted  10,138,730   1.79         
Exercised  (127,799
)
  2.79         
Forfeited  (5,816,858
)
  3.76         
Outstanding at September 30, 2023  23,621,828  $2.86   8.46  $1,129 
Options exercisable at September 30, 2023  6,311,402  $
3.98   6.38  $286 
Vested and expected to vest at September 30, 2023  19,261,890  $2.96   8.29  $916 
Restricted stock units
During the nine months ended September 30, 2023, the Company granted 491,320 restricted stock unit (“RSU”) awards. Stock-based compensation related to RSU awards for the three months ended September 30, 20202023 and 2022 was $8 and $2,175, respectively.  Stock-based compensation related to RSU awards for the period from June 10, 2020 (inception) throughnine months ended September 30, 2020,2023 and 2022 was $1,186 and $1,930, respectively.

A summary of the RSU activity is presented in the table below:

  
Number
of Shares
Underlying
RSUs
  
Weighted
Average
Grant-Date
Fair Value
 
Outstanding non-vested RSUs at December 31, 2022  2,018,449  $8.41
 
Granted  491,320   1.76 
Vested  (1,655,978)  8.56 
Forfeited
  (213,117)  7.09 
Outstanding non-vested RSUs at September 30, 2023  640,674  $3.39 
The Company’s stock-based compensation is allocated to the following operating expense categories as follows:

  Three months ended September 30,  Nine months ended September 30, 
  2023
  2022
  2023
  2022
 
Research and development $479  $1,114  $2,531  $3,460 
Selling, general and administrative  662   2,929   4,383   3,639 
Total stock-based compensation
 $1,141  $4,043  $6,914  $7,099 

10. NET LOSS PER SHARE

Basic net loss per share is computed by dividing the net loss by the weighted averageweighted-average number of Class A redeemableshares of common stock since issuance. of the Company outstanding during the period. Diluted net loss per share is computed by giving effect to all common share equivalents of the Company, including those presented in the table below, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all common share equivalents would have been anti-dilutive.
The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock:

 
 Three months ended September 30,  Nine months ended September 30, 
  2023
  2022
  2023
  2022
 
Numerator            
Net loss 
$
(24,728
)
 
$
(31,713
)
 
$
(73,912
)
 
$
(99,302
)
Numerator for basic and diluted EPS - loss attributable to common stockholders $(24,728) $(31,713) $(73,912) $(99,302)
Denominator                
Common stock
  141,660,018
   139,542,660
   141,154,110
   139,057,663
 
Denominator for basic and diluted EPS - weighted-average common stock  141,660,018
   139,542,660
   141,154,110
   139,057,663
 
Basic and diluted net loss per share $(0.17) $(0.23) $(0.52) $(0.71)

Net loss per common share basic and diluted forattributable to Class A and Class B non-redeemable common stock is calculated by dividingstockholders was the net income (loss), less income attributable to Class A redeemablesame on a basic and diluted basis, as the inclusion of all potential common stock, by the weighted average number of Class A and Class B non-redeemable common stockequivalent shares outstanding for the periods. Class B non-redeemable common stock includes the Founder Shares and Private Placement Units as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.


HIGHCAPE CAPITAL ACQUISITION CORP.
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2020
(Unaudited)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying condensed balance sheet, primarily due to their short-term nature.

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect onbeen anti-dilutive. Anti-dilutive common equivalent shares were as follows:


  September 30, 
  2023
  2022
 
Outstanding options to purchase common stock
  23,621,828
   12,245,302 
Outstanding restricted stock units
  640,674
   2,084,710 
Outstanding warrants
  3,968,319
   3,968,319 
   28,230,821
   18,298,331 


11. WARRANT LIABILITIES

Public Warrants
As of September 30, 2023 and December 31, 2022, there were an aggregate of 3,833,319 outstanding Public Warrants, which entitle the Company’s unaudited condensed financial statements.

NOTE 3. INITIAL PUBLIC OFFERING

Pursuantholder to the Initial Public Offering, the Company sold 11,500,000 Units, which included the full exercise by the underwriters of their over-allotment option in the amount of 1,500,000 Units, at a price of $10.00 per Unit. Each Unit consists of one share ofacquire Class A common stock and one-third of one redeemable warrant (“Public Warrant”).stock. Each whole Public Warrantwarrant entitles the registered holder to purchase one share of Class A common stock at aan exercise price of $11.50 per share, subject to adjustment (see Note 7).

NOTE 4. PRIVATE PLACEMENT

Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 405,000 Private Placement Units at a price of $10.00 per Private Placement Unit, for an aggregate purchase price of $4,050,000. Each Private Placement Unit consists of one share of Class A common stock (“Private Placement Share” or, collectively, “Private Placement Shares”) and one-third of one warrant (each, a “Private Placement Warrant”). Each whole Private Placement Warrant is exercisable to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment. A portion of the proceeds from the Private Placement Units were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law), and the Private Placement Units and all underlying securitiesas discussed below, beginning on September 9, 2021. The warrants will expire worthless.

NOTE 5. RELATED PARTY TRANSACTIONS

Founder Shares

Onon June 10, 2020, the Company issued an aggregate of 2,875,000 shares of Class B common stock to the Sponsor (the “Founder Shares”) for an aggregate price of $25,000. On June 30, 2020, the Sponsor transferred 30,000 Founder Shares to each of its three independent directors, or an aggregate of 90,000 Founder Shares, resulting in the Sponsor holding an aggregate of 2,785,000 Founder Shares. The Founder Shares included an aggregate of up to 375,000 shares subject to forfeiture to the extent that the underwriters’ over-allotment option was not exercised in full or in part, so that the number of Founder Shares would equal 20% of the Company’s issued and outstanding shares after the Initial Public Offering (not including the Private Placement Shares). As a result of the underwriters’ election to fully exercise their over-allotment option, 375,000 Founder Shares are no longer subject to forfeiture.

The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) one year after the completion of a Business Combination and (B) subsequent to a Business Combination, (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Public Stockholders having the right to exchange their shares of common stock for cash, securities or other property.


HIGHCAPE CAPITAL ACQUISITION CORP.
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2020
(Unaudited)

Promissory Note — Related Party

On June 10, 2020, the Sponsor issued an unsecured promissory note to the Company (the “Promissory Note”), pursuant to which the Company could borrow up to an aggregate principal amount of $300,000, of which $99,627 was outstanding under the Promissory Note as of September 9, 2020. The Promissory Note was non-interest bearing and payable on the earlier of June 10, 2021 or the consummation of the Initial Public Offering. The Promissory Note was repaid in full on September 15, 2020.

Related Party Loans

In addition, in order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans may be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into units upon consummation of the Business Combination at a price of $10.00 per unit. The units would be identical to the Private Placement Units. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of September 30, 2020, there were no amounts outstanding under the Working Capital Loans.

Administrative Support Agreement

The Company entered into an agreement, commencing on September 3, 2020, to pay an affiliate of the Sponsor a total of up to $10,000 per month for office space, secretarial and administrative support. Upon completion of a Business Combination or its liquidation, the Company will cease paying these monthly fees. The Company incurred $25,000 fees for these services for the three months ended September 30, 2020 and for the period from June 10, 2020 (inception) through September 30, 2020, of which $25,000 is included in accounts payable and accrued expenses in the accompanying condensed balance sheet at September 30, 2020.

NOTE 6. COMMITMENTS AND CONTINGENCIES

Risks and Uncertainties

Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position and/or search for a target company, the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Registration Rights

Pursuant to a registration rights agreement entered into on September 3, 2020, the holders of the Founder Shares, Private Placement Units, Private Placement Shares, Private Placement Warrants and securities that may be issued upon conversion of Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the Founder Shares) are entitled to registration rights, requiring the Company to register such securities and any other securities of the Company acquired by them prior to the consummation of a Business Combination for resale. The holders of these securities will be entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $4,025,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.


HIGHCAPE CAPITAL ACQUISITION CORP.
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2020
(Unaudited)

NOTE 7. STOCKHOLDERS’ EQUITY

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. At September 30, 2020, there were no shares of preferred stock issued or outstanding.

Class A Common Stock — The Company is authorized to issue 380,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. At September 30, 2020, there were 1,182,364 shares of Class A common stock issued and outstanding, excluding 10,722,636 Class A common stock subject to possible redemption.

Class B Common Stock — The Company is authorized to issue 20,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. At September 30, 2020, there were 2,875,000 shares of Class B common stock issued and outstanding.

Only holders of the Class B common stock will have the right to vote on the election of directors prior to the Business Combination. Holders of Class A common stock and holders of Class B common stock will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law.

The shares of Class B common stock will automatically convert into Class A common stock immediately following the completion of the Business Combination, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in connection with a Business Combination the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the total number of shares of Class A common stock outstanding after such conversion (after giving effect to any redemptions of shares of Class A common stock by public stockholders and excluding the Private Placement Shares underlying the Private Placement Warrants), including the total number of shares of Class A common stock issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of a Business Combination, excluding any shares of Class A common stock or equity-linked securities or rights exercisable for or convertible into shares of Class A common stock issued, or to be issued, to any seller in a Business Combination and any Private Placement Units issued to the Sponsor, officers or directors upon conversion of Working Capital Loans, provided that such conversion of Founder Shares will never occur on a less than one-for-one basis.

Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination2026 or earlier upon redemption or liquidation.

The Company will not be obligated to deliver

Redemptions

At any shares of Class A common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Class A common stock underlyingtime while the warrants is then effective and a current prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue shares of Class A common stock upon exercise of a warrant unless the shares of Class A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.

The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of a Business Combination, it will use its best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Class A common stock issuable upon exercise of the Public Warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the shares of Class A common stock issuable upon exercise of the warrants is not effective by the sixtieth (60th) business day after the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. Notwithstanding the above, if the Class A common stock are at the time of any exercise of a Public Warrant, not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their Public Warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, the shares under applicable blue sky laws to the extent an exemption is not available.


HIGHCAPE CAPITAL ACQUISITION CORP.
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2020
(Unaudited)

Once the warrants become exercisable, the Company may redeem not less than all of the outstanding Public Warrants:



in whole and not in part;


at a price of $0.01 per warrant;


upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and


if, and only if, the closing price of the Company’s common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to the warrant holders.


If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

In addition, if (x)foregoing conditions are satisfied and the Company issues additionala notice of redemption of the Public Warrants at $0.01 per warrant, each holder of Public Warrants will be entitled to exercise held Public Warrants prior to the scheduled redemption date.

If the Company calls the Public Warrants for redemption for $0.01 as described above, the Company’s Board of Directors may elect to require any holder that wishes to exercise his, her or its Public Warrants to do so on a “cashless basis.” If the Company’s Board of Directors makes such election, all holders of Public Warrants would pay the exercise price by surrendering their warrants for that number of shares of Class A common stock or equity-linked securities for capital raising purposes in connection withequal to the closingquotient obtained by dividing (x) the product of a Business Combination at an issue price or effective issue pricethe number of less than $9.20 per shareshares of Class A common stock (with such issueunderlying the warrants, multiplied by the excess of the “fair market value” ​over the exercise price or effective issueof the warrants by (y) the “fair market value”. For purposes of the redemption provisions of the warrants, the “fair market value” means the average last reported sale price of the Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.
The Company evaluated the Public Warrants under ASC 815-40, in conjunction with the SEC Division of Corporation Finance’s April 12, 2021 Public Statement, Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”) (the “SEC Statement”), and concluded that they do not meet the criteria to be determinedclassified in good faith bystockholders’ equity. Specifically, the Company’s boardexercise of directors, and,the warrants may be settled in cash upon the caseoccurrence of any such issuance toa tender offer or exchange offer in which the Sponsormaker of the tender offer or its affiliates, without taking into account any Founder Shares held byexchange offer, upon completion of the Sponsortender offer or its affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances representexchange offer, beneficially owns more than 60%50% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the completion of a Business Combination (net of redemptions), and (z) the volume weighted average trading priceoutstanding shares of the Company’s Class A common stock, during the 20 trading day period starting on the trading day after the day on which the Company completeseven if it would not result in a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise pricechange of control of the Company. This provision would preclude the warrants willfrom being classified in equity and thus the warrants should be adjusted (to the nearest cent) to be equal to 115%classified as a liability.
Private Warrants
As of the higher of the Market ValueSeptember 30, 2023 and the Newly Issued Price, and the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

December 31, 2022, there were 135,000 Private Warrants outstanding. The Private Placement Warrants are identical to the Public Warrants, underlying the Units sold in the Initial Public Offering, except that (1)so long as they are held by the Sponsor or any of its permitted transferees, (i) the Private Placement Warrants and the shares of Class A common stock issuable upon the exercise of the Private Placement Warrants willwere not be transferable, assignable or saleable until 30 days after the completion of athe Business Combination, subject to certain limited exceptions, (2)(ii) the Private Placement Warrants will be exercisable for cash or on a cashless basis, (3)at the holder’s option, and (iii) the Private Placement Warrants will be non-redeemable so longare not subject to the Company’s redemption option at the price of $0.01 per warrant. The Private Warrants are subject to the Company’s redemption option at the price of $0.01 per warrant, provided that the other conditions of such redemption are met, as they are held by the initial purchasers or their permitted transferees, and (4) the holders of the Private Placement Warrants and the Class A common stock issuable upon the exercise of the Private Placement Warrants will have certain registration rights.described above. If the Private Placement Warrants are held by someonea holder other than the initial purchasersSponsor or theirany of its permitted transferees, the Private Placement Warrants will be redeemable by the Company in all redemption scenarios applicable to the Public Warrants and exercisable by such holders on the same basis as the Public Warrants.

NOTE 8. FAIR VALUE MEASUREMENTS

 At September 30, 2020, assets held

The Company evaluated the Private Warrants under ASC 815-40, in conjunction with the Trust Account were comprisedSEC Statement, and concluded that they do not meet the criteria to be classified in stockholders’ equity. Specifically, the terms of $115,000,384the warrants provide for potential changes to the settlement amounts depending upon the characteristics of the warrant holder, and, because the holder of a warrant is not an input into the pricing of a fixed-for-fixed option on equity shares, such provision would preclude the warrant from being classified in money market funds, which are invested in U.S. Treasury Securities. Duringequity and thus the period from June 10, 2020 (inception) through September 30, 2020, the Company did not withdraw any interest income from the Trust Account.

warrant has been classified as a liability.

 
The fair value of warrant liabilities was $1,077 and $996 as of September 30, 2023 and December 31, 2022, respectively.  The Company recognized losses of $162 and $81 as a Change in fair value of warrant liabilities in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2023, respectively. The Company recognized gains of $137 and $5,121 as a Change in fair value of warrant liabilities in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022, respectively. There were no exercises or redemptions of the Public Warrants or Private Warrants during the three and nine months ended September 30, 2023 or 2022.

12. INCOME TAXES
Income taxes for the three and nine months ended September 30, 2023 and 2022 are recorded at the Company’s financialestimated annual effective income tax rate, subject to adjustments for discrete events, if they occur. The Company’s estimated annual effective tax rate was 0.0% for the three and nine months ended September 30, 2023 and 2022. The primary reconciling items between the federal statutory rate of 21.0% for these periods and the Company’s overall effective tax rate of 0.0% were related to the effects of deferred state income taxes, nondeductible stock-based compensation, changes in the fair value of warrant liabilities, research and development credits, and the valuation allowance recorded against the full amount of its net deferred tax assets.

A valuation allowance is required when it is more likely than not that some portion or all of the Company’s deferred tax assets will not be realized. The realization of deferred tax assets depends on the generation of sufficient future taxable income during the period in which the Company’s related temporary differences become deductible. The Company has recorded a full valuation allowance against its net deferred tax assets as of September 30, 2023 and liabilities reflects management’s estimateDecember 31, 2022 since management believes that based on the earnings history of amountsthe Company, it is more likely than not that the benefits of these assets will not be realized.

13. RELATED PARTY TRANSACTIONS
The Company utilized and subleased office and laboratory space in a building owned by a related party. The Company paid $0 and $80 under month-to-month lease arrangements for this space for the three months ended September 30, 2023 and 2022, respectively, and $156 and $241 for the nine months ended September 30, 2023 and 2022, respectively. The Company no longer subleases this space as of June 30, 2023.

The Company was a party to an Amended and Restated Technology Services Agreement (the “ARTSA”), most recently amended on November 11, 2020, by and among 4Catalyzer Corporation (“4C”), the Company and other participant companies controlled by Dr. Jonathan Rothberg, the Chairman of the Company’s Board of Directors. The Company entered into a First Addendum to the ARTSA on February 17, 2021 pursuant to which the Company agreed to terminate its participation under the ARTSA no later than immediately prior to the effective time of the Business Combination, resulting in the termination of the Company’s participation under the ARTSA on June 10, 2021. In connection with the termination of the Company’s participation under the ARTSA, the Company terminated its lease agreement with 4C and negotiated an arm’s length lease agreement. Under the ARTSA, the Company and the other participant companies had agreed to share certain non-core technologies, which means any technologies, information or equipment owned or otherwise controlled by the participant company that are not specifically related to the core business area of the participant and subject to certain restrictions on use. The ARTSA also provided for 4C to perform certain services for the Company and each other participant company such as monthly administrative, management and technical consulting services to the Company which were pre-funded approximately once per quarter. The Company incurred expenses of $65 and $149, which included $24 and $44 under month-to-month sublease arrangements for office and laboratory spaces from 4C, during the three months ended September 30, 2023 and 2022, respectively.The Company incurred expenses of $323 and $517, which included $72 and $141 under month-to-month sublease arrangements for office and laboratory spaces from 4C, during the nine months ended September 30, 2023 and 2022, respectively. The amounts advanced and due to 4C at September 30, 2023 and December 31, 2022 related to operating expenses were $20 and $70, respectively, which are included in Accrued expenses and other current liabilities on the condensed consolidated balance sheets. The amounts advanced and due from 4C at September 30, 2023 and December 31, 2022, related to operating expenses were $0 and $37, respectively, and are included in Prepaid expenses and other current assets on the condensed consolidated balance sheets.

The ARTSA also provided for the participant companies to provide other services to each other. The Company also had transactions with other entities under common ownership, which included payments made to third parties on behalf of the Company and payments made by the Company to third parties on behalf of the other entities. There were no amounts remaining payable to the Company or from the Company at September 30, 2023 and December 31, 2022.

On September 20, 2021, the Company entered into a Binders Collaboration (the “Collaboration”) with Protein Evolution, Inc. (“PEI”) to develop technology and methods in the field of nanobodies and potentially other binders to produce novel biological reagents and related data. The Collaboration was made pursuant to and governed by the Technology and Services Exchange Agreement, effective as of June 10, 2021, by and among the Company and the participants named therein, including PEI. Dr. Rothberg serves as Chairman of the Board of Directors of PEI and the Rothberg family are controlling stockholders of PEI. Effective March 31, 2022, the Collaboration with PEI was terminated, and the Company paid a final payment of $1,135 under the Collaboration for all services rendered.

Effective October 1, 2022, the Company entered into a Protein Engineering Collaboration (the “New Collaboration”) with PEI to develop technology and methods in the field of nanobodies and potentially other binders to produce novel biological reagents and related data. The New Collaboration was made pursuant to and governed by the Technology and Services Exchange Agreement, effective as of June 10, 2021, by and among the Company and the participants named therein, including PEI. Dr. Rothberg serves as Chairman of the Board of Directors of PEI and the Rothberg family are controlling stockholders of PEI. The Company incurred expenses of $47 and $172 during the three and nine months ended September 30, 2023, respectively, related to the New Collaboration. The amounts advanced and due from PEI at September 30, 2023 and December 31, 2022 related to operating expenses were $217 and $45, respectively, and are included in Prepaid expenses and other current assets on the condensed consolidated balance sheets.

Effective November 1, 2022, the Company entered into an Advisory Agreement with Dr. Rothberg (the “Advisory Agreement”), pursuant to which Dr. Rothberg serves as Chairman of the Board, advises the Chief Executive Officer and the Board on strategic matters, and provides consulting, business development and similar services on matters relating to our current, future and potential scientific and strategic initiatives and such other consulting services reasonably requested from time to time. Pursuant to the Advisory Agreement, as compensation for the services provided thereunder, in March 2023, the Company granted Dr. Rothberg an option to purchase 250,000 shares of Class A common stock pursuant to the 2021 Plan. In connection with the Advisory Agreement, Dr. Rothberg’s title was changed from Executive Chairman to Chairman of the Board.

Dr. Rothberg also receives fees as the Chairman of the Company’s Board of Directors and a member of the Board and Nominating and Corporate Governance Committee. The Company paid $27 and $113 to Dr. Rothberg for the three months ended September 30, 2023 and 2022, respectively, and $87 and $341 for the nine months ended September 30, 2023 and 2022, respectively, for all services provided to the Company.


14. RESTRUCTURING



The Company committed to organizational restructurings, during the quarters ended March 31, 2023 and September 30, 2023, designed to decrease its costs and create a more streamlined organization to support its business. As of September 30, 2023, the Company has recorded a $551 restructuring liability, which is included in Accrued expenses and other current liabilities in the condensed consolidated balance sheets.


The Company’s restructuring costs, primarily for cash severance costs and other severance benefits, are allocated to the following operating expense categories as follows:

  Three months ended  Nine months ended 
  September 30, 2023  September 30, 2023 
Research and development
 
$
1,602
  
$
2,738
 
Selling, general and administrative  
649
   
1,393
 
Total restructuring costs $2,251  $4,131 

15. COMMITMENTS AND CONTINGENCIES
Commitments
Licenses related to certain intellectual property:
The Company licenses certain intellectual property, some of which may be utilized in its current or future product offerings. To preserve the right to use such intellectual property, the Company is required to make annual minimum fixed payments totaling $210 as well as royalties based on net sales if the royalties exceed annual minimum fixed payments. As of September 30, 2023, the Company recorded $155 in Accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Other commitments:
The Company sponsors a 401(k) defined contribution plan covering all eligible U.S. employees. Contributions to the 401(k) plan are discretionary. The Company did not make any matching contributions to the 401(k) plan for the three and nine months ended September 30, 2023 and 2022.
Contingencies
The Company is subject to claims in the ordinary course of business. Except as discussed below, the Company is not currently a party to any pending or threatened litigation, the outcome of which would be expected to have receiveda material adverse effect on its financial condition, results of operations, or cash flows. The Company accrues contingent liabilities to the extent that the liability is probable and estimable.

In October 2023, a former contract manufacturer of the Company filed a complaint alleging breach of contract and made claims for economic damage and attorney costs. Although it is not possible to determine the potential financial exposure associated with the alleged claims given its early stage, the Company believes that it has a meritorious defense and intends to vigorously defend against all claims asserted in the complaint.
The Company enters into agreements that contain indemnification provisions with other parties in the ordinary course of business, including business partners, investors, contractors, and the Company’s officers, directors and certain employees. The Company has agreed to indemnify and defend the indemnified party claims and related losses suffered or incurred by the indemnified party from actual or threatened third-party claims because of the Company’s activities or non-compliance with certain representations and warranties made by the Company. It is not possible to determine the maximum potential loss under these indemnification provisions due to the Company’s limited history of prior indemnification claims and the unique facts and circumstances involved in any particular case. To date, losses recorded in the Company’s condensed consolidated statements of operations and comprehensive loss in connection with the saleindemnification provisions have not been material.


HIGHCAPE CAPITAL ACQUISITION CORP.
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 2020
(Unaudited)

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at September 30, 2020 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

Description Level  

September 30,

2020

 
Assets:        
Cash and cash equivalents held in Trust Account – U.S. Treasury Securities Money Market Fund  1  $115,000,384 

NOTE 9. SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued, November 12, 2020. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.


ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to HighCape Capital Acquisition Corp. References to our “management” or our “management team” refer to our officers and directors, references to the “Sponsor” refer to HighCape Capital Acquisition, LLC.
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations


The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our condensed consolidated results of operations and financial condition. The discussion should be read in conjunction with (i) the unaudited condensed consolidated financial statements and notes thereto contained in this Quarterly Report on Form 10-Q, (ii) the consolidated financial statements and notes thereto for the year ended December 31, 2022 contained in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2023 and (iii) our other public reports filed with the SEC. This discussion contains forward looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2022, and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023. Actual results may differ materially from those contained in any forward-looking statements. Unless the context otherwise requires, references to “we”, “us”, “our”, the “Company” or “Quantum-Si” are intended to mean the business and operations of Quantum-Si Incorporated and its consolidated subsidiaries. The unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023 and 2022, respectively, present the financial position and results of operations of Quantum-Si Incorporated and its consolidated subsidiaries.

Overview

We are an innovative life sciences company with the mission of transforming single-molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome, the set of proteins expressed within a cell. We have developed a proprietary universal single-molecule detection platform that we are first applying to proteomics to enable Next-Generation Protein SequencingTM (“NGPS”), the ability to sequence proteins in a massively parallel fashion (rather than sequentially, one at a time), that can be used for the study of nucleic acids. We believe that with the ability to sequence proteins in a massively parallel fashion and offer a simplified workflow with a faster turnaround time, NGPS has the potential to unlock significant biological information through improved resolution and unbiased access to the proteome at a speed and scale that is not available today. Traditionally, proteomic workflows to sequence proteins required days or weeks to complete. Our platform, as originally planned, was designed to offer an end to end workflow including both sample preparation and sequencing and was comprised of Carbon™, our automated sample preparation instrument, our Platinum™ NGPS instrument, the Quantum-Si Cloud software service, and reagent kits and chips for use with our instruments.  In 2021, we introduced our PlatinumTM early access program to sites with participation from leading academic centers and key industry partners. The early access program introduced the PlatinumTM single-molecule sequencing system to key opinion leaders across the globe, for both expansion and development of applications and workflows. We launched the PlatinumTM instrument and started to take orders in December 2022, and subsequently began commercial shipments of Platinum™ in January 2023.

Since our initial launch of the PlatinumTM instrument, we have found that, consistent with other proteomics detection technologies, customers select the biological sample type and sample preparation method they use. The range of sample types and sample prep methods utilized in proteomics is extensive and often some level of optimization is required to make them compatible with the downstream detection technology. Our initial platform contemplated Carbon™ as an automated sample preparation instrument. While Carbon™ could help reduce sample preparation variation and streamline the end-to-end workflow in utilizing our PlatinumTM protein sequencing instrument, it is not an absolute requirement, and may not be the best solution long-term. To this end, we recently completed an evaluation of Carbon™ as it relates to the workflow and in comparison to other potential liquid handler and sample preparation solutions. This evaluation concluded that pursuing efforts to continue development of CarbonTM was not the most effective use of our research and development efforts and therefore we have paused development related to Carbon™ to focus efforts on PlatinumTM, our reagent kits and chips for use on PlatinumTM, and our Quantum-Si Cloud environment as our go forward platform to maximize value.

Now that our Platinum™ and Quantum-Si Cloud system has launched, we intend to follow a systematic, phased approach to continue to successfully launch updates to our platform. We believe we are the first company to successfully enable NGPS on a semiconductor chip, thus digitizing a massive proteomics opportunity, which allows for a massively parallel solution at the ultimate level of sensitivity —single-molecule detection.

We believe that our platform offers a differentiated workflow solution in a rapidly evolving proteomics tools market. Within our initial focus market of proteomics, our workflow is designed to provide users a seamless opportunity to gain key insights into the immediate state of biological pathways and cell state. Our platform aims to address many of the key challenges and bottlenecks with legacy proteomic solutions, such as mass spectrometry (“MS”), high instrument costs both in terms of acquisition and ownership and complexity with data analysis, which together prevent broad adoption. We believe our platform, which is designed to streamline sequencing and data analysis at a lower instrument cost than legacy proteomic solutions, could allow our product to have wide utility across the study of the proteome. For example, our platform could be used for biomarker discovery and disease detection, pathway analysis, immune response, and vaccine development, among other applications.

Total revenue for the three and nine months ended September 30, 2023 was $0.2 million and $0.7 million, respectively. We define backlog as purchase orders or signed contracts from our customers for which we have not fulfilled and therefore have not yet recognized the associated revenue. We anticipate converting this backlog to revenue in the subsequent quarters; however, our ability to do so is subject to customers who may seek to cancel or delay their orders even if we are prepared to fulfill them. As of September 30, 2023, our backlog was approximately $0.1 million.

Global Developments

In 2022, various central banks around the world (including the Federal Reserve in the United States) raised interest rates. These rate increases have caused a decline in the fair value of our fixed income mutual funds to date. The impact of such rate changes on the overall financial markets and the economy may continue to impact us in the future, including by making capital more difficult and costly to obtain on reasonable terms and when needed. In addition, the global economy has experienced and is continuing to experience high levels of inflation and global supply chain disruptions. We continue to monitor these supply chain, inflation and interest rate factors, as well as the uncertainty resulting from the overall economic environment.

In addition, although we have no operations in or direct exposure to Russia or Ukraine, we have experienced some constraints in product and material availability and increasing costs required to obtain some materials and supplies as a result of the impact of the Russia-Ukraine military conflict on the global economy, which has contributed to the global supply chain disruptions. To date, our business has not been materially impacted by the conflict. However, as the conflict continues or worsens, it may adversely impact our business, financial condition, results of operations or cash flows.

Recent Developments

In April 2023, we informed the contract manufacturer who manufactures our PlatinumTM and CarbonTM instruments that we intend to wind down the relationship and transition to a different contract manufacturer. In October 2023, we were informed that the contract manufacturer had filed a complaint alleging breach of contract and made claims for economic damage under the contract as well as attorney costs. Although it is not possible to determine the potential financial exposure associated with the alleged claim at the point given its early stage, we believe that we have a meritorious defense and intend to vigorously defend against all claims asserted in the complaint.

In August 2023, we filed a universal shelf registration statement on Form S-3 (the “Shelf Registration Statement”), which became effective on August 22, 2023, covering the offering of Class A common stock, preferred stock, debt securities, warrants, rights and units.

In August 2023, we also entered into an Equity Distribution Agreement (“EDA”) with an outside placement agent (the “Agent”), under which we may, from time to time, sell shares of our Class A common stock having an aggregate offering price of up to $75 million in “at-the-market” offerings through the Agent (the “ATM Offering”). The Shelf Registration Statement included a prospectus supplement covering the offering, issuance and sale of up to $75 million of our Class A common stock, from time to time, through the ATM Offering. The shares to be sold under the EDA may be issued and sold pursuant to the Shelf Registration Statement. The EDA also provides that the Agent will be entitled to compensation for its services in an amount up to 3.0% of the gross proceeds from the sales of shares sold through the Agent under the EDA. We have no obligation to sell any shares under the EDA and may at any time suspend solicitation and offers under the EDA. To date, we have not issued or sold any shares of our Class A common stock under the ATM Offering.

Description of Certain Components of Financial Data

Revenue

Revenue is derived from sales of products and services. Product revenue is generated from the following sources: (i) instrument sales of our PlatinumTM instrument and (ii) consumables, which consist of sales of our sequencing reagents, chips, and library reagents. Service revenue is generated from service maintenance contracts including cloud access, proof of concept services and advanced training for instrument use. Freight revenue is recognized as Product revenue in the condensed consolidated statements of operations and comprehensive loss upon product shipment.

See Note 2 “Summary of Significant Accounting Policies” in our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for further information regarding our revenue recognition policies.

Cost of revenue

Cost of revenue primarily consists of product and service costs including material costs, personnel costs and benefits, inbound and outbound freight, packaging, warranty replacement costs, royalty costs, facilities costs, depreciation and amortization expense, and inventory obsolescence and write-offs.

Research and development

Research and development expenses primarily consist of personnel costs and benefits, stock-based compensation, lab supplies, consulting and professional services, fabrication services, facilities costs, depreciation and amortization expense, software, and other outsourced expenses. Research and development expenses are expensed as incurred. All of our research and development expenses are related to developing new products and services.

Selling, general and administrative

Selling, general and administrative expenses primarily consist of personnel costs and benefits, stock-based compensation, patent and filing fees, consulting and professional services, legal and accounting services, facilities costs, depreciation and amortization expense, insurance and office expenses, product advertising and marketing.

Dividend income

Dividend income primarily consists of dividends earned on fixed income mutual funds classified as marketable securities.

Unrealized gain (loss) on marketable securities

Unrealized gain (loss) on marketable securities primarily consists of unrealized gains/(losses) on fixed income mutual funds in marketable securities.

Realized loss on marketable securities

Realized loss on marketable securities primarily consists of realized losses on fixed income mutual funds in marketable securities.

Change in fair value of warrant liabilities

Change in fair value of warrant liabilities primarily consists of the change in the fair value of our publicly traded warrants (the “Public Warrants”) and our warrants sold in a private placement (the “Private Warrants”).

Other income (expense), net

Other income (expense), net primarily consists of a change in the fair value of the Majelac Technologies LLC (“Majelac”) contingent consideration.

Provision for income taxes

We utilize the asset and liability method of accounting for income taxes where deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities using the enacted statutory tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is established against net deferred tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the net deferred tax assets will not be realized. We recorded a full valuation allowance as of September 30, 2023 and 2022. Based on the available evidence, we believe that it is more likely than not that we will be unable to utilize all of our deferred tax assets in the future.

Results of Operations

The following is a discussion of our results of operations for the three and nine months ended September 30, 2023 and 2022 and our accounting policies are described in Note 2 “Summary of Significant Accounting Policies” in our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

  Three months ended September 30,  Nine months ended September 30, 
(in thousands, except for % changes) 2023  2022  % Change  2023  2022  % Change 
Revenue:                  
Product $216  $-  nm  $654  $-  nm 
Service  7   -  nm   28   -  nm 
Total revenue  223   -  nm   682   -  nm 
Cost of revenue  115   -  nm   372   -  nm 
Gross profit  108   -  nm   310   -  nm 
Operating expenses:                      
Research and development  16,587   16,675   (0.5)%  50,588   53,905   (6.2)%
Selling, general and administrative  10,696   10,983   (2.6)%  33,010   31,093   6.2%
Total operating expenses  27,283   27,658   (1.4)%  83,598   84,998   (1.6)%
Loss from operations  (27,175)  (27,658)  (1.7)%  (83,288)  (84,998)  (2.0)%
Dividend income  2,572   1,381   86.2%  7,274   3,288   121.2%
Unrealized gain (loss) on marketable securities  1,953   (4,240)  (146.1)%  8,302   (20,384)  (140.7)%
Realized loss on marketable securities  (1,901)  (1,348)  41.0%  (6,489)  (2,399)  170.5%
Change in fair value of warrant liabilities  (162)  137   (218.2)%  (81)  5,121   (101.6)%
Other income (expense), net  (15)  15   (200.0)%  370   70   428.6%
Loss before provision for income taxes  (24,728)  (31,713)  (22.0)%  (73,912)  (99,302)  (25.6)%
Provision for income taxes  -   -  nm   -   -  nm 
Net loss and comprehensive loss $(24,728) $(31,713)  (22.0)% $(73,912) $(99,302)  (25.6)%

Comparison of the Three Months Ended September 30, 2023 and 2022

Revenue, Cost of revenue and Gross profit

  
Three months ended
September 30,
  Change
(in thousands, except for % changes) 2023  2022  Amount %
Total revenue $223  $-  $223 nm
Cost of revenue  115   -   115 nm
Gross profit  108   -   108 nm
Gross profit margin  48.4% nm        

We launched the PlatinumTM instrument and started to take orders in December 2022, and subsequently began commercial shipments of PlatinumTM in January 2023. Total revenue recognized in the three months ended September 30, 2023 was $0.2 million for the sale of PlatinumTM instruments and kits. No revenue was recognized in 2022. Gross profit was $0.1 million for the three months ended September 30, 2023.

Research and development

  
Three months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Research and development $16,587  $16,675  $(88)  (0.5)%

Research and development expenses decreased by $0.1 million, or 0.5%, for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. The decrease was primarily due to refined research and development activities coupled with a decrease in headcount due to restructuring activities initiated in the first and third quarters of 2023.

Selling, general and administrative

  
Three months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Selling, general and administrative $10,696  $10,983  $(287)  (2.6)%

Selling, general and administrative expenses decreased by $0.3 million, or 2.6%, for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. The decrease was primarily due to a decrease of $2.3 million of stock-based compensation as a result of the restructuring activities initiated in the first and third quarters of 2023, partially offset by an increase of $1.1 million in personnel costs primarily due to increased headcount for the ramp up of commercial sales and restructuring costs and an increase of $0.9 million of expenses primarily for consulting, legal and professional fees and insurances.

Dividend income

  
Three months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Dividend income $2,572  $1,381  $1,191   86.2%

Dividend income increased by $1.2 million, or 86.2%, for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 as a result of higher dividends earned on invested marketable securities.

Unrealized gain (loss) on marketable securities

  
Three months ended
September 30
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Unrealized gain (loss) on marketable securities $1,953  $(4,240) $6,193   (146.1)%

Unrealized gain (loss) increased by $6.2 million, or 146.1%, for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 as a result of an increase in unrealized gains as a result of the market adjustments of investments in marketable securities, which consist of fixed income mutual funds.

Realized loss on marketable securities

  
Three months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Realized loss on marketable securities $(1,901) $(1,348) $(553)  41.0%

Realized loss on marketable securities increased by $0.6 million, or 41.0%, for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 primarily as a result of an increase in realized losses from sales of marketable securities.

Change in fair value of warrant liabilities

  
Three months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Change in fair value of warrant liabilities $(162) $137  $(299)  (218.2)%

The change in fair value of warrant liabilities decreased by $0.3 million, or 218.2%, for the three months ended September 30, 2023 compared to the three months ended September 30, 2022 primarily due to a decline in the Company’s underlying common stock price.

Other income (expense), net

  
Three months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Other income (expense), net $(15) $15  $(30)  (200.0)%

Other income (expense), net remained flat for the three months ended September 30, 2023 compared to the three months ended September 30, 2022.

Comparison of the Nine Months Ended September 30, 2023 and 2022

Revenue, Cost of revenue and Gross profit

  
Nine months ended
September 30,
  Change
(in thousands, except for % changes) 2023  2022  Amount %
Total revenue $682  $-  $682 nm
Cost of revenue  372   -   372 nm
Gross profit  310   -   310 nm
Gross profit margin  45.5% nm        

Total revenue recognized in the nine months ended September 30, 2023 was $0.7 million for the sale of PlatinumTM instruments and kits. No revenue was recognized in 2022. Gross profit was $0.3 million for the nine months ended September 30, 2023.

Research and development

  
Nine months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Research and development $50,588  $53,905  $(3,317)  (6.2)%

Research and development expenses decreased by $3.3 million, or 6.2%, for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022. The decrease was primarily due to refined research and development activities coupled with a decrease in headcount due to restructuring activities initiated in the first and third quarters of 2023 and collaboration fees, which includes $1.1 million paid to Protein Evolution, Inc. in 2022.

Selling, general and administrative

  
Nine months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Selling, general and administrative $33,010  $31,093  $1,917   6.2%

Selling, general and administrative expenses increased by $1.9 million, or 6.2%, for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022. The increase was primarily due to an increase of $1.7 million in personnel costs primarily due to increased headcount for the ramp up of commercial sales and restructuring costs and an increase of $0.7 million of stock-based compensation, partially offset by a decrease of $0.5 million of expenses primarily for consulting, legal and professional fees and insurances.

Dividend income

  Nine months ended September 30,  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Dividend income $7,274  $3,288  $3,986   121.2%

Dividend income increased by $4.0 million, or 121.2%, for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 as a result of higher dividends earned on invested marketable securities.

Unrealized gain (loss) on marketable securities

  
Nine months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Unrealized gain (loss) on marketable securities $8,302  $(20,384) $28,686   (140.7)%

Unrealized gain (loss) on marketable securities increased by $28.7 million, or 140.7%, for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 primarily as a result of an increase in unrealized gains as a result of the market adjustments of investments in marketable securities, which consist of fixed income mutual funds.

Realized loss on marketable securities

  
Nine months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Realized loss on marketable securities $(6,489) $(2,399) $(4,090)  170.5%

Realized loss on marketable securities increased by $4.1 million, or 170.5%, for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 primarily as a result of an increase in realized losses from sales of marketable securities.

Change in fair value of warrant liabilities

  
Nine months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Change in fair value of warrant liabilities $(81) $5,121  $(5,202)  (101.6)%

The change in fair value of warrant liabilities decreased by $5.2 million, or 101.6%, for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 primarily due to a decline in the Company’s underlying common stock price.

Other income (expense), net

  
Nine months ended
September 30,
  Change 
(in thousands, except for % changes) 2023  2022  Amount  % 
Other income (expense), net $370  $70  $300   428.6%

Other income (expense), net increased by $0.3 million, or 428.6%, for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022 primarily as a result of a gain of $0.4 million recorded on the Majelac contingent consideration.

Liquidity and Capital Resources

Since our inception, we have funded our operations primarily with proceeds from the issuance of equity to private investors, as well as with the $511.2 million in proceeds received from the closing of the Business Combination on June 10, 2021. Additionally, we began to generate revenue during 2023. Our primary uses of liquidity have been operating expenses, capital expenditures and our acquisition of certain assets of Majelac. Cash flows from operations have been historically negative as we continue to invest in the development of our technology in NGPS. We expect to incur negative operating cash flows on an annual basis for the foreseeable future until such time that we can scale our revenue growth.

We expect that our existing cash and cash equivalents and investments in marketable securities, together with revenue from the sale of our products and services, will be sufficient to meet our liquidity, capital expenditure, and anticipated working capital requirements and fund our operations for at least the next 12 months. We expect to use our cash and cash equivalents and investments in marketable securities and funds from revenue generated to invest in our continued commercialization efforts, to further invest in research and development, for other operating expenses, business acquisitions and for working capital and general corporate purposes.

As of September 30, 2023, we had cash and cash equivalents and investments in marketable securities totaling $274.6 million. Our future capital requirements may vary from those currently planned and will depend on various factors including the pace and success of product commercialization.

We launched the PlatinumTM instrument and started to take orders in December 2022, and subsequently began commercial shipments of Platinum™ in January 2023. In addition, we are continuing further research and development efforts to enhance our Platinum™ instrument. Based on these initiatives and activities, our business will require an accelerated amount of spending to enhance the sales and marketing teams, continue to drive development, and build inventory. Other factors that could accelerate cash needs include: (i) delays in achieving scientific and technical milestones; (ii) unforeseen capital expenditures and fabrication costs related to manufacturing for commercialization; (iii) changes we may make in our business or commercialization strategy; (iv) costs of running a public company; (v) other items affecting our forecasted level of expenditures and use of cash resources, including potential acquisitions; and (vi) increased product and service costs.

In August 2023, we filed the Shelf Registration Statement, which became effective on August 22, 2023.

In August 2023, we also entered into the EDA with the Agent, under which we may, from time to time, sell shares of our Class A common stock under the ATM Offering. The Shelf Registration Statement included a prospectus supplement covering the offering, issuance and sale of up to $75 million of our Class A common stock, from time to time, through the ATM Offering. The shares to be sold under the EDA may be issued and sold pursuant to the Shelf Registration Statement. The EDA also provides that the Agent will be entitled to compensation for its services in an amount up to 3.0% of the gross proceeds from the sales of shares sold through the Agent under the EDA. We have no obligation to sell any shares under the EDA and may at any time suspend solicitation and offers under the EDA. To date, we have not issued or sold any shares of our Class A common stock under the ATM Offering.

In the future, we may be unable to obtain any required additional financing on terms favorable to us, if at all. If adequate funds are not available to us on acceptable terms or otherwise, we may be unable to successfully develop or enhance products and services, respond to competitive pressure or take advantage of acquisition opportunities, any of which could have a material adverse effect on our business, financial condition, operating results and cash flows.

Cash flows

The following table summarizes our cash flows for the periods indicated:

  
Nine months ended
September 30,
 
(in thousands) 2023  2022 
Net cash (used in) provided by:      
Net cash used in operating activities $(73,067) $(70,977)
Net cash provided by investing activities  82,360   111,684 
Net cash provided by financing activities  210   1,771 
Net increase in cash and cash equivalents $9,503  $42,478 

Net cash used in operating activities

The net cash used in operating activities of $73.1 million for the nine months ended September 30, 2023 was due primarily to a net loss of $73.9 million resulting from continued spend on research and development efforts and commercialization ramp up, net cash outflows from changes in operating assets and liabilities of $8.5 million and unrealized gains on marketable securities of $8.3 million, partially offset by stock-based compensation of $6.9 million, realized losses on marketable securities of $6.5 million and depreciation and amortization of $3.1 million.

The net cash used in operating activities of $71.0 million for the nine months ended September 30, 2022 was due primarily to a net loss of $99.3 million and a change in fair value of warrant liabilities of $5.1 million, partially offset by unrealized losses on marketable securities of $20.4 million, stock-based compensation of $7.1 million and realized losses on marketable securities of $2.4 million.

Net cash provided by investing activities

The net cash provided by investing activities of $82.4 million in the nine months ended September 30, 2023 was due primarily to sales of marketable securities of $88.0 million, offset by purchases of property and equipment of $4.9 million and capitalized internally developed software costs of $0.8 million.

The net cash provided by investing activities of $111.7 million in the nine months ended September 30, 2022 was due primarily to sales of marketable securities of $119.8 million, partially offset by purchases of property and equipment of $7.2 million and marketable securities of $0.8 million.

Net cash provided by financing activities

The net cash provided by financing activities of $0.2 million in the nine months ended September 30, 2023 was due primarily from $0.4 million from proceeds from exercise of stock options offset by $0.1 million of deferred offering costs paid for the S-3 shelf registrations and ATM.

The net cash provided by financing activities of $1.8 million in the nine months ended September 30, 2022 was due primarily from $2.6 million from proceeds from exercise of stock options, offset by $0.5 million from payment of deferred consideration and $0.3 million from payment of contingent consideration related to the Majelac acquisition.

Contractual Obligations

We lease certain facilities and equipment under non-cancellable lease agreements that expire at various dates through 2032. As of September 30, 2023, the future payments, before adjustments for tenant incentives, under leases was $32.2 million, which includes a lease we entered into in December 2021 for a facility in New Haven, Connecticut, which commenced in January 2022, and a lease that commenced in April 2022 for a facility in Branford, Connecticut.

Licenses related to certain intellectual property

We license certain intellectual property, some of which may be utilized in our current or future product offerings. To preserve the right to use such intellectual property, we are required to make annual minimum fixed payments totaling approximately $0.2 million as well as royalties based on net sales if the royalties exceed annual minimum fixed payments.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations should be read in conjunction with the unauditedis based on our condensed consolidated financial statements, and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s final prospectus for its Initial Public Offering filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

We are a blank check company incorporated on June 10, 2020 as a Delaware corporation and formed for the purpose of effecting a merger, capital stock businesses. We intend to effectuate our initial Business Combination using cash from the proceeds of our Initial Public Offering and the private placement of the Private Placement Units, the proceeds of the sale of our shares in connection with our initial Business Combination, shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, or a combination of the foregoing.

We expect to continue to incur significant costs in the pursuit of our initial Business Combination. We cannot assure you that our plans to complete our initial Business Combination will be successful.

Results of Operations

We have neither engaged in any operations nor generated any revenues to date. Our only activities from inception through September 30, 2020 were organizational activities, those necessary to prepare for our Initial Public Offering, described below, and, after our Initial Public Offering, identifying a target company for an initial Business Combination. We do not expect to generate any operating revenues until after the completion of our initial Business Combination. We generate non-operating income in the form of interest income on marketable securities held in the Trust Account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

For the three months ended September 30, 2020, we had a net loss of $50,253, which consists of formation and operating costs of $50,637, offset by interest income on marketable securities held in the Trust Account of $384.

For the period from June 10, 2020 (inception) through September 30, 2020, we had a net loss of $51,253, which consists of formation and operating costs of $51,637, offset by interest income on marketable securities held in the Trust Account of $384.

Liquidity and Capital Resources

Until the consummation of the Initial Public Offering, the Company’s only source of liquidity was an initial purchase of Class B ordinary shares by our Sponsor and loans from our Sponsor.

On September 9, 2020, we consummated our Initial Public Offering of 11,500,000 Units, inclusive of the full exercise by the underwriters of their over-allotment option in the amount of 1,500,000 Units, at a price of $10.00 per Unit, generating gross proceeds of $115,000,000. Simultaneously with the closing of our Initial Public Offering, we consummated the sale of 405,000 Private Placement Units to the Sponsor at a price of $10.00 per Unit, generating gross proceeds of $4,050,000.


Following our Initial Public Offering, the full exercise of the over-allotment option and the sale of the Private Placement Units, a total of $115,000,000 was placed in the Trust Account. We incurred $6,797,377 in transaction costs, including $2,300,000 of underwriting fees, $4,025,000 of deferred underwriting fees and $472,377 of other costs.

For the period from June 10, 2020 (inception) through September 30, 2020, cash used in operating activities was $182,900. Net loss of $51,253 was affected by interest earned on marketable securities held in the Trust Account of $384 and changes in operating assets and liabilities, which used $131,263 of cash from operating activities.

As of September 30, 2020, we had cash and marketable securities of $115,000,384 held in the Trust Account. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less taxes paid and deferred underwriting commissions) to complete our initial Business Combination. We may withdraw interest to pay taxes. During the period ended September 30, 2020, we did not withdraw any interest earned on the Trust Account. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our initial Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

As of September 30, 2020, we had cash of $1,164,723 outside of the Trust Account. We intend to use the funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, and structure, negotiate and complete our initial Business Combination.

In order to fund working capital deficiencies or finance transaction costs in connection with our initial Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required. If we complete our initial Business Combination, we would repay such loaned amounts. In the event that our initial Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used for such repayment. Up to $1,500,000 of such loans may be convertible into units identical to the Private Placement Units, at a price of $10.00 per unit at the option of the lender.

We do not currently believe we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating our initial Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our initial Business Combination. Moreover, we may need to obtain additional financing either to complete our initial Business Combination or because we become obligated to redeem a significant number of our Public Shares upon consummation of our initial Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our initial Business Combination. If we are unable to complete our initial Business Combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the Trust Account. In addition, following our initial Business Combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.

Off-Balance Sheet Financing Arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of September 30, 2020. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual Obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than an agreement to pay an affiliate of the Sponsor a monthly fee up to $10,000 for office space, secretarial and administrative support services. We began incurring these fees on September 3, 2020 and will continue to incur these fees monthly until the earlier of the completion of the Business Combination and our liquidation.

The underwriters are entitled to a deferred fee of $4,025,000prepared in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.


Critical Accounting Policies

accordance with U.S. GAAP. The preparation of unauditedthese condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires managementus to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and income andas well as expenses incurred during the periods reported.reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about items that are not readily apparent from other sources. Actual results could materiallymay differ from these estimates under different assumptions or conditions.


Revenue Recognition

Revenue is derived from sales of products and services. Product revenue is primarily generated from the sales of instrument and consumables used in protein sequencing and analysis.  Service revenue is primarily generated from service maintenance contracts including cloud access, proof of concept services and advanced training for instrument use. Freight revenue is recognized as Product revenue in the condensed consolidated statements of operations and comprehensive loss upon product shipment.

We recognize revenue when control of our products and services is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those estimates.products and services. This process involves identifying the contract with a customer, determining the distinct performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. Revenue recognition for contracts with multiple deliverables is based on the separate satisfaction of each distinct performance obligation within the contract. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have identifiedtransferred control of a good or service to the following critical accounting policies:

Class A Common Stock Subjectcustomer, meaning the customer has the ability to Possible Redemption

use and obtain the benefit of the good or service. We allocate transaction price to the performance obligations in a contract with a customer, based on the relative standalone selling price of each performance obligation. We determine standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, we estimate the standalone selling price taking into account available information and specific factors such as competitive positioning, internal costs, profit objectives, and internally approved pricing guidelines related to the performance obligation.


Our performance obligation for our Class A common stock subjectsales of products is considered satisfied upon shipment of the goods to possible redemptionthe customer in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemptionshipping terms (either upon shipment or delivery), which is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that are either within thewhen control of the holderproduct is deemed to be transferred; this would include instruments and consumables. Customers generally do not have a right of return, except for defective or subject to redemptiondamaged products during the warranty period or unless prior written consent is provided. In instances where right of payment or transfer of title is contingent upon the occurrencecustomer’s acceptance of uncertain events not solely within our control)the product, revenue is classifieddeferred until all acceptance criteria have been met. Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as temporary equity. At all other times, common stock is classified as stockholders’ equity. Our common stock features certain redemption rights thatfulfillment costs and are included in Cost of revenue in the condensed consolidated statements of operations and comprehensive loss. Shipping and handling costs billed to customers are considered to be outsidepart of the transaction price and are recognized as revenue with the underlying product sales. Revenues for service maintenance contracts, which start after the first year of purchase and are considered as service type warranties that effectively extend the standard first-year warranty coverage at the customer’s option, are recognized ratably over the contract service period as these services are performed evenly over time. Revenues for proof of concept services and advanced training is recognized upon satisfaction of the underlying performance obligation. We typically provide a standard one-year warranty which covers defects in materials and workmanship and manufacturing or performance conditions including bug fixes under normal use and service for the first year. The first year of the warranty of our controlproducts is considered an assurance-type warranty and subjectwe have determined that this standard first-year warranty is not a distinct performance obligation. Deferred revenue primarily consists of billings and payments received in advance of revenue recognition from service maintenance contracts including cloud access, proof of concept services and advanced training, and is reduced as the revenue recognition criteria are met.

There have been no additional material changes to occurrence of uncertain future events. Accordingly,our critical accounting policies and estimates as compared to the Class A common stock subject to possible redemption is presented as temporary equity, outside of the stockholders’ equity section ofcritical accounting policies and estimates disclosed in our unaudited condensed balance sheet.

Net Loss per Common Share

We apply the two-class method in calculating earnings per share. Net income per common share, basic and diluted for Class A redeemable common stock is calculated by dividing the interest income earnedAnnual Report on the Trust Account, net of applicable taxes, by the weighted average number of shares of Class A redeemable common stock outstandingForm 10-K for the periods. Net income per common share, basicyear ended December 31, 2022, filed with the SEC on March 17, 2023.


See Note 2 “Summary of Significant Accounting Policies” in our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for further information regarding our significant accounting policies and diluted for and Class B non-redeemable common stock is calculated by dividing net income less income attributable to Class estimates.

Recently Issued Accounting Pronouncements

A redeemable common stock, by the weighted average numberdescription of shares of Class B non-redeemable common stock outstanding for the periods presented.

Recent Accounting Standards

Management does not believe that any recently issued but not yet effective, accounting standards, if currently adopted, would have a material effectpronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 “Summary of Significant Accounting Policies – Recently Issued Accounting Pronouncements” in our condensed consolidated financial statements included elsewhere in this Quarterly Report on our unaudited condensed financial statements.

Form 10-Q.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Item 3.Quantitative and Qualitative Disclosures About Market Risk


Inflation risk

We do not believe that inflation has had a material effect on our business, financial condition, results of operations or cash flows, other than its impact on the general economy. Nonetheless, to the extent our costs are impacted by general inflationary pressures, we may not be able to fully offset such higher costs through price increases or manufacturing efficiencies. Our inability or failure to do so could harm our business, financial condition, results of operations or cash flows.

Interest rate risk

Our marketable securities are comprised primarily of investments in fixed income mutual funds. The primary objective of our investments is the preservation of capital to fulfill liquidity needs. We do not enter into investments for trading or speculative purposes. Interest rate increases have resulted in changes in the fair value of our fixed income mutual funds to date. As of September 30, 2020,2023, this cumulative impact is a net unrealized loss of $12.9 million. The impact of such rate changes on the overall financial markets and the economy may continue to impact us in the future.

Foreign Currency Risk

Presently, we were not subject to any market or interest rate risk. Followingoperate our business primarily within the consummationUnited States and currently execute the majority of our Initial Public Offering, the net proceeds received into the Trust Account, have been investedtransactions in U.S. government treasury bills, notes or bondsdollars. This limited foreign currency translation risk is not expected to have a material impact on our condensed consolidated financial statements. To date, we have not entered into any hedging arrangements with a maturity of 185 days or less orrespect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to managing our risk relating to fluctuations in certain money market funds that invest solely in US treasuries. Due to the short-term nature of these investments, we believe there will be no associated material exposure to interest rate risk.

currency rates.

ITEM 4. CONTROLS AND PROCEDURES

Item 4.Controls and Procedures


Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

As required by Rules 13a-15 and 15d-15 under Based on the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as of September 30, 2020. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were effective.

effective as of September 30, 2023.


Changes in Internal Control Overover Financial Reporting

During


We began commercial shipments of the most recently completed fiscalPlatinum™ protein sequencing instrument in the first quarter there has beenof 2023. We are in the process of implementing additional controls over the processes that are associated with the commercial launch of PlatinumTM including but not limited to revenue recognition and inventory. There were no changeadditional changes in our internal control over financial reporting during the quarter ended September 30, 2023 that hashave materially affected, or isare reasonably likely to materially affect, our internal control over financial reporting.



PART II - OTHER INFORMATION


ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1.
LEGAL PROCEEDINGS.

We are not currently a party to any material legal proceedings.

ITEM 1A. RISK FACTORS.

Factors that could cause
ITEM 1A.RISK FACTORS.


Our business, results of operations and financial condition are subject to various risks and uncertainties including the risk factors described under the caption “Risk Factors” in our actual results to differ materially from thoseAnnual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 17, 2023, in thisour Quarterly Report are any ofon Form 10-Q for the risks described in our final prospectus for our Initial Public Offeringquarter ended March 31, 2023 filed, with the SEC on September 4, 2020. Any of these factors could resultMay 11, 2023, in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report there have been no material changes toon Form 10-Q for the risk factors disclosed in our final prospectus for our Initial Public Offeringquarter ended June 30, 2023 filed, with the SEC on September 4, 2020. August 7, 2023 and the risk factor described below.

We rely on certain contract manufacturers to manufacture and supply components of both our instruments and consumable offerings. If these manufacturers should fail or not perform satisfactorily, our ability to commercialize and supply our instruments and consumable offerings would be adversely affected.

We rely on certain contract manufacturers to manufacture and supply components of both our instruments and consumable offerings. Since our contracts with these manufacturers do not commit them to carry inventory or make available any particular quantities, these manufacturers may disclose changesgive other customers’ needs higher priority than ours, and we may not be able to such factorsobtain adequate supplies in a timely manner or disclose additional factors from timeon commercially reasonable terms. Further, if these manufacturers are unable to timeobtain critical components used in our future filingsinstruments or supply our instruments on the timelines we require, our business and commercialization efforts would be harmed.  In November 2021, we acquired one of our key suppliers in the semiconductor chip assembly and packaging business, Majelac.

In the event it becomes necessary to utilize a different contract manufacturer for our products, we would experience additional costs, delays and difficulties in doing so as a result of identifying and entering into an agreement with a new manufacturer as well as preparing such new manufacturer to meet the SEC.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On September 9, 2020,logistical requirements associated with manufacturing our instruments and consumable offerings, and our business would suffer. In addition, once our products are authorized for use by the FDA as medical devices, we consummatedwill need to contract with FDA-registered device establishments that are able to comply with current Good Manufacturing Practice requirements that are set forth in the QSR, unless explicitly exempted by regulation.  We are presently working to transition activities of one of our Initial Public Offeringcontract manufacturers that produces a component of 11,500,000 Units, inclusive of underwriters’ electionour semi-conductor chips.  The existing contract manufacturer is moving their operations to fully exercise their over-allotment option,a new facility, which has been delayed, requiring us to transition to a new contract manufacturer.  If we sold an additional 1,500,000 Units. The Units were soldare unable to begin manufacturing at an offering price of $10.00 per Unit, generating total gross proceeds of $115,000,000. Cantor Fitzgerald & Co. acted as the sole book running managerthis new contract manufacturer in a timely fashion, it will affect our ability to produce semi-conductor chips which would harm our research and development efforts and commercial operations.


In addition, certain of the offering. The securities soldcomponents and consumables used in our instruments and consumable offerings are sourced from a limited number, or sole suppliers. If we were to lose such a supplier, there can be no assurance that we will be able to identify or enter into an agreement with an alternative supplier on a timely basis on acceptable terms, if at all. An interruption in our ability to sell and deliver instruments or consumable offerings to customers could occur if we encounter delays or difficulties in securing these components or consumables, or if the quality of the components or consumables supplied do not meet specifications, or if we cannot then obtain an acceptable substitute. Our suppliers have also been impacted by the COVID-19 pandemic, and in the offering were registered under thepast, we have experienced supply delays for critical hardware and instrumentation as a result. If any of these events occur, our business, results of operations, financial condition and prospects could be harmed.

ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES.

Unregistered Sales of Equity Securities Act on a registration statement on Form S-1 (No. 333-240283). The SEC declared the registration statement effective on September 3, 2020.

Simultaneously with the consummationand Use of the Initial Public Offering and the option to purchase additional Units, we consummated a private placementProceeds


Not applicable.

Issuer Purchases of 405,000 Private Placement Units to our Sponsor at a price of $10.00 per Private Placement Unit, generating total proceeds of $4,050,000. Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2) of theEquity Securities Act.

Of the gross proceeds received from the Initial Public Offering and the full exercise of the option to purchase additional Units, $115,000,000 was placed in the Trust Account.

We paid a total of $2,300,000 in underwriting discounts and commissions and $472,377 for other offering costs and expenses related to the Initial Public Offering. In addition, the underwriters agreed to defer $4,025,000 in underwriting discounts and commissions.

For a description of the use of the proceeds generated in our Initial Public Offering, see Part I, Item 2 of this Form 10-Q.


Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

ITEM 3.DEFAULTS UPON SENIOR SECURITIES.


Not applicable.


ITEM 4.
MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5.OTHER INFORMATION.


Not applicable.

ITEM 5. OTHER INFORMATION.

None. 

ITEM 6. EXHIBITS.

ITEM 6.EXHIBITS


The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.


No.
Exhibit
Number
Exhibit DescriptionFiled Herewith
Incorporated by
Reference Herein
from
Form or Schedule
Filing Date
SEC File/​
Reg. Number
 Description of Exhibit
1.1UnderwritingEquity Distribution Agreement, dated September 3, 2020,as of August 11, 2023, by and between the CompanyQuantum-Si Incorporated and Cantor Fitzgerald & Co. (1)
3.1Evercore Group L.L.C. Amended and Restated Certificate of Incorporation. (1)
4.1 
Form S-3
(Exhibit 1.2)
8/11/2023333-273934
Separation Agreement, dated September 3, 2020,as of July 18, 2023, by and between the CompanyQuantum-Si Incorporated and Continental Stock Transfer & Trust Company, as warrant agent. (1)
10.1Michael P. McKenna, Ph.D.
 
Form 8-K
(Exhibit 10.1)
7/20/2023001-39486
Separation Agreement, dated as of September 3, 2020, by and among the Company, its officers, its directors and HighCape Capital Acquisition LLC. (1)
10.2Investment Management Trust Agreement, dated September 3, 2020,1, 2023 by and between the CompanyQuantum-Si Incorporated and Continental Stock Transfer & Trust Company, as trustee. (1)
10.3Patrick Schneider, Ph.D.
 Registration Rights Agreement, dated September 3, 2020, by and among the Company, HighCape Capital Acquisition LLC and the other holders party thereto. (1)
10.4 Private Placement Units Purchase Agreement, dated September 3, 2020, by and among the Company and HighCape Capital Acquisition LLC. (1)
10.5
Form 8-K
(Exhibit 10.1)
 Administrative Services Agreement, dated September 3, 2020, by and between the Company and HighCape Capital Acquisition LLC. (1)
31.1*9/5/2023 001-39486
Certification of the Principal Executive Officer and Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuantpursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2* X
Certification of the Principal ExecutiveFinancial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuantpursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1** X
Certification of the Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuantpursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
32.2** 
Certification of the Principal ExecutiveFinancial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuantpursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS* X
101.INSInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.CAL*​X 
101.SCHInline XBRL Taxonomy Extension Schema Document​X
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*​X XBRL Taxonomy Extension Schema Document
101.DEF* 
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*​X 
101.LABInline XBRL Taxonomy Extension LabelsLabel Linkbase Document
101.PRE*​X 
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document​X
104Cover Page Interactive Data File (embedded within the Inline XBRL document)​X


+Management contract or compensatory plan or arrangement.

*Filed herewith.
**Furnished herewith.
(1)Previously filedThe certifications attached as an exhibit to our CurrentExhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 8-K10-Q are not deemed filed on September 9, 2020with the Securities and Exchange Commission and are not to be incorporated by reference herein.into any filing of Quantum-Si Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective of any general incorporation language contained in such filing.

18


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 HIGHCAPE CAPITAL ACQUISITION CORP.QUANTUM-SI INCORPORATED
   
Date: November 12, 20209, 2023By:/s/ Kevin RakinJeffrey Hawkins
 Name:Kevin Rakin
Title:Chief Executive Officer
  (PrincipalJeffrey Hawkins
President and Chief Executive Officer)
   
Date: November 12, 20209, 2023By:/s/ Matt ZugaJeffry Keyes
 Name: Matt Zuga
Title:Chief Financial Officer
  (PrincipalJeffry Keyes
Chief Financial and Accounting Officer)Officer


 


36